

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 02/060379 A2

(51) International Patent Classification⁷: **A61K**

(21) International Application Number: PCT/US01/50424

(22) International Filing Date: 24 October 2001 (24.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00 1 25784.1 25 October 2000 (25.10.2000) CN

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US Not furnished (CIP)
Filed on Not furnished

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

(71) Applicants (*for all designated States except US*): NATIONAL ENGINEERING RESEARCH CENTER FOR TRADITIONAL CHINESE MEDICINE [CN/CN]; Room 448 No. 1 Building 351, Guoshoujing Road, Pudong New Area, Shanghai, P.R. China 201203 (CN). INTERNATIONAL HERBAL PHARMACEUTICALS, CORP. [US/US]; Suite 604, 141-07 20th Avenue, Whitestone, NY 11357 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SHEN, Ping, Niang [CN/CN]; Room 605, Yichuan Wu Cun No. 71, Shanghai 200065 (CN). RUAN, Ke, Feng [CN/CN]; Room 1403, East Luo Chuan Road No. 2, Lane 494, Shanghai 200072 (CN). WANG, Yu, Lan [CN/CN]; Room 1306, East Luo Chuan Road No. 2, Lane 494, Shanghai 200072 (CN). YU, Wei [CN/CN]; Room 405, Building 12, Meilong Road No. 130, Shanghai 200237 (CN). ZHANG, Wen, Qing [CN/CN]; Room 115, Building 3, Mei Long Road 130, Shanghai 200237 (CN). HONG, Xiao, Kun [CN/CN]; Room 401, Yao Xue Building, Lingling Road No. 530, Shanghai 200030 (CN). WANG, Xin, Hong [CN/CN]; Room 403, Yao Xue Building, Lingling Road No. 530, Shanghai 200030 (CN).

(74) Agents: CHAN, Albert, Wai-Kit et al.; 59-42 Parsons Boulevard, Flushing, NY 11365-1433 (US).

— as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

[Continued on next page]

(54) Title: COMPOSITION COMPRISING EXTRACTS OF FLOS LONICERAE, FRUCTUS FORSYTHIAE AND RADIX SCUTELLARIAE, USES AND PREPARATION THEREOF

(57) Abstract: The invention provides a new formulation of the composition comprising *Flos Lonicerae Fructus Forsythiae* and *Radix scutellariae*. This invention also provides a method for identification with HPLC and the characteristic peaks of the compositions of said composition. The composition possesses antiviral effective, namely, inhibition of influenza virus, parainfluenza virus, herpes I virus and herpes II virus. The invention refers to a method for preparation and control of the active components of *Flos Lonicerae Fructus Forsythiae* and *Radix Scutellariae* for its biological activity. The invention also provides a unique raw material and intermediate formulation.



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**COMPOSITION COMPRISING EXTRACTS OF FLOS LONICERAE, FRUCTUS
FORSYTHIAE AND RADIX SCUTELLARIAE, USES
AND PREPARATION THEREOF**

5

Throughout this application, various publications are referenced to and the disclosures of these publications are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to the skilled therein as of this date of the invention described and claimed herein.

BACKGROUND OF THE INVENTION

This invention relates to a composition comprising extracts of flos lonicerae, fructus forsythiae and radix scutellariae, uses and preparation thereof. This composition could be used for the inhibition of influenza virus, parainfluenza virus, herpes I virus and herpes II virus.

20

Influenza is the most frequent cause of acute respiratory illness that could require medical intervention. It affects all age groups and it can recur to any individual. A study involving some residents of a nursing home that suffer from respiratory viral diseases was conducted between 1988 and 1999. The results showed a thirty-day mortality of 4.7% (15/322) for influenza A, 5.4% (7/129) for influenza B, 6.1% (3/49) for parainfluenza type I, 0% (0/26) for parainfluenza type II, type III and type IV, 0% (0/26) for respiratory syncytial virus (RSV), and 1.6% (1/61) for rhinovirus. The herpes simplex virus infection is an important risk factor caused cervical carcinoma, AIDS, Alzheimer's disease. The rates of herpes simplex virus (HSV) infection are rising, the highest prevalence

25
30

being in the group infected with the Human Immunodeficiency Virus (HIV).

During the past three decades, efforts to prevent and control influenza have focused primarily on the use of inactivated influenza vaccines in elderly people and in individuals with chronic medical conditions. However, the continuing impact of influenza in these and other population groups has motivated the development of novel approaches for prevention and control of influenza. Several important advances in the field of influenza have occurred in the last few years. New antiviral drugs based on the structure of the neuraminidase molecule were assessed in clinical trials and found to be effective against influenza A and B viruses. In recent year, the research and development of nature products for influenza virus and herpes simplex virus are gradually increasing in importance. Studies from Dr. Mori K, Kampo Pharmacology Department, Central Research Laboratories, Tsumara of Japan showed that the Hochu-ekki-to (TJ-41), a Japanese herbal medicine was found to increase the survival rate of mice, prolong the mean survival days, and suppress viral growth in bronchoalveolar labage fluid (BALF). This medicine inhibited the lung index (lung consolidation) four days after the mice were infected with influenza. The agent had been administered 7 days before injection of the virus and 4 days after injection. The results suggested that the TJ-41 exerts its inhibitory effects over the influenza virus infection via enhancement of the host immune responses in this experimental murine system. Dr. Mantani N, Department of Japanese Oriental Medicine, Toyama Medical and Pharmaceutical University, conducted a vital fluorescence microscopic study. It showed that the extract of Ephedrae herba (EHext) inhibited acidification

of endosomes and lysosomes in a concentration-dependent manner (100-400 mg/ml). Moreover the growth of influenza A/PR/8/34 (H1N1) (PR8) virus was inhibited when the cells were treated with EHext for one hour immediately after infection, or treated as early as 5-10 min after the infection.

Gingyo-san is a natural product containing extracts from seven medicinal plants and fermented soybeans in a specific ratio. It has been used as a therapeutic agent for the common cold in China. Dr. Kurokawa M, Department of Virology, Toyama Medical and Pharmaceutical University of Japan, found that two components extracted from Glycyrrhizae radix and Arctii Fructus presented anti-influenza viral activities in mice infected with influenza A2 virus. Dr. Yamada H, Oriental Medicine Research Center, Kitasato Institute of Japan studied the anti-virus activity of Sho-seiryu-to (SST). He suggested that SST was useful for influenza virus infection on aged people and for cross-protection of subtypes of influenza A viruses and influenza B virus, and was also useful for the treatment of patients who had a history of influenza virus infection and/or influenza vaccination. Dr. Hayashi K, Department of Virology, Toyama Medical and Pharmaceutical University studied the activities of thirteen sesquiterpenes isolated from *Tripterygium wilfordii* Hook fil. var. *regelii* Makino against herpes simplex virus type 1 (HSV-1) in vitro. He found that the triptofordin C-2 suppressed viral protein synthesis of infected cells when added at the early steps of the HSV-1 replication and exerted inhibition of translation of the transcripts of the immediate early genes. Radix bupleuri, a Chinese medicinal herb used for the treatment of influenza, malaria and menstrual disorders, was extracted with hot

water and separated into five different fractions (RB, RBI, RBII, RBIII and RBIV) by stepwise alcohol precipitation. Dr. Kok LD, Department of Biochemistry, Chinese University of Hong Kong, found that RBIII
5 exhibited a potent activating effect on the cytotoxic activity of macrophages, NK and LAK cells against tumor cells in his studies. Dr. Ball MA investigated the antiviral effect of the Keishi-ni-eppi-ichi-to (TJS-064) in mice infected with the influenza A2 (H2N2) virus. The
10 result showed that pulmonary consolidations, virus titers in lung tissues and HAI titers in sera of infected mice treated with TJS-064 were all significantly lower compare with those of infected mice treated with saline. Dr. Fu HY presented the decoction of Gui Zhi Tang (DGZT), which had
15 the action of bidirectional regulation and normalization in polyhidrosis induced by aminopyrine or in the case of hypohidrosis induced by ropineonrats.

The product obtained from this invention is an effective
20 agent for inhibition of influenza virus, parainfluenza virus, herpes I virus and herpes II virus. The composition of this Chinese herbal medicine comprises three herbal components: *Radix Scutellariae*, *Fructus Forsythiae* and *Flos Lonicerae*. The pharmacological characteristics and
25 efficacy relating to the compositions had been confirmed in previous studies.

Wang YH, the Second Hospital of Harbin Medical University, presented a result of clinical research in his
30 publication. Two hundred and two cases of acute respiratory tract infection (ARI) were treated with Shuanghuanglian (SHL) aerosol, an antiviral agent. Among them, 64% of the cases were caused from Respiratory Syncytial Virus (RSV). The virostatic and bacteriostatic

tests were done in vitro by the cell culture method. The results showed that SHL could inhibit the RSV, parainfluenza I-IV and 23 kinds of pathogenic bacteria such as the *Staphylococcus aureus*. The bacteriostatic effect was positively correlated to the SHL concentration. Experimental studies showed that SHL could enhance the NK cell activity, promote the production of alpha-interferon and raise the rate of lymphocyte transformation. The controlled observation on SHL preparation with various dosage-forms revealed that the SHL aerosol was effective in treating early ARI. This drug showed better results when compare to the results from the injections and oral liquor symptom etiologically ($P < 0.01$). Its effective rate was 96%.

Some studies were conducted with herbal products for anti-inflammation or/and anti-virus, which include herbal components comprising *Radix Scutellariae* or *Fructus Forsythiae* or *Flos Lonicerae*. However, there were differences of the formula, content and efficiency of effective composition compared with the invention.

US Pat No.5908628 refers to a therapeutic composition for the treatment of pain, fever and inflammation, which includes some herbal components, one of them is *Fructus Forsythiae*. The percentage of *Fructus Forsythiae* is only 5-15% and the range of weight is 170-190g in the composition.

In US Pat No.5834000, a pharmacologically effective composition was studied. The composition, comprising *Isatides tinctoria*, *Forsythia fructus*, *Lonicera flos* et al, showed antiviral and antimicrobial activities. The weight percent of *Isatides tinctoria* is about 37.5%, and

5% of *Forsythia fructus* and *Lonicera flos*. *Forsythia fructus* and *Lonicera flos* can relieve sore throat symptoms and reduce fever without unwanted side effects. There is a difference in the percentage and composition of effective ingredients when compared with this invention of which the percentage of *Forsythia fructus* is about 50% and for the *Lonicera flos* is 25%.

US Pat No.5989556 pertains to the compositions derived from Chinese herbal medicines, medicinal plants and extracts thereof, which are used for treatment of infected animals, especially those with hepatitis B and C viruses (HBV & HCV), and Human Immunodeficiency Virus (HIV). The compositions contain *forsythiae fructus*, *loniceræ flos* or *scutellariae* in various groups.

The SHL agent is extracted with ancient techniques that have been used in traditional Chinese medicine for a long period of time. In the early 70's, the SHL was used to treat upper respiratory tract infection. The statistics from Pediatrics Department of Haerbin Medical University of China indicated that the effective rate of pediatric pneumonia was about 92.5% and the cure rate was around 80.8%. In the early 90's, the Ministry of Public Health of China approved different kinds of devices for the use of SHL such as powder injection, water injection, oral liquid, aerosol and tablet. But none of these devices were very effective in the way they were produced and administered.

30

This invention is the second development of the SHL tablet. The technique of preparation, composition and efficacy for the treatment of inhibition of influenza

virus, parainfluenza virus, herpes I virus and herpes II virus were further improved in this invention.

This invention refers to an herbal composition that
5 inhibits the influenza virus, parainfluenza virus, herpes
I virus and herpes II virus. This invention derives from
an herbal composition. Wherein said composition comprises
Flos Lonicerae, *Fructus Forsythiae*, *Radix Scutellariae*.
This invention includes a method for identification with
10 HPLC and the characteristic peaks of the compositions of
the raw materials, drug substances and drug product. The
invention refers to a special extraction, wherein said
extraction comprises CO₂ supercritical fluid extraction
consisting of *Flos Lonicerae* and *Fructus Forsythiae*,
15 subboiling aqueous extraction, flocculation and alcohol
precipitation. The invention refers to a unique
intermediate formulae, wherein said formulae comprises
about 90-180g of drug substance of 10-60g of *Flos*
Lonicerae and *Fructus Forsythiae*, 10-60g of supercritical
20 extracta of *Flos Lonicerae* and *Fructus Forsythiae* and
about 30-50g of *Radix Scutellariae* extract. This current
preparation was made more effective than the one used in
previous techniques.

25

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS.1 shows the process of Chitosan preparation.

FIGS.2 shows the 3D-Spectro-Chromatogram of *Flos Lonicerae*
raw material, wherein the numbers of peaks are about 8
30 through 11. The 4th peak is a certified
characteristic/comparable peak of Chlorogenic acid.

FIGS.3 shows the 3D-Spectro-Chromatogram of *Fructus*
Forsythiae raw material, wherein the numbers of peaks are

about 11 through 14. The 8th peak is a certified characteristic/comparable peak of Phillyrin.

FIGS.4 shows the 3D-Spectro-Chromatogram of Radix Scutellariae raw material, wherein the numbers of peaks
5 are about 22 through 25. The 12th peak is a certified characteristic/comparable peak of Baicalin and the 21st peak is a certified characteristic /comparable peak of Baicalein.

FIGS.5 shows the 3D-Spectro-Chromatogram of the extracts
10 of Flos Lonicerae and Fructus Forsythiae, wherein the numbers of peaks are about 18 through 21. The 8th, the 10th and the 16th peaks sequentially is the certified characteristic peaks of Chlorogenic acid, Caffeic acid and Phillyrin.

FIGS.6 shows the 3D-Spectro-Chromatogram of Radix Scutellariae extract, wherein the numbers of peaks are about 4 through 5. The 1st peak is a certified characteristic peak of Baicalin. The 5th peak is a certified characteristic peak of Baicalein.

FIGS.7 shows the 3D-Spectro-Chromatogram of the drug product comprising Flos Lonicerae, Fructus Forsythiae, Radix Scutellariae, wherein the numbers of peaks are about 27 through 30. The 8th, the 12th, the 20th, the 22nd and the 28th peaks is respectively the certified characteristic
25 peaks of Chlorogenic acid, Caffeic acid, Phillyrin, Baicalin and Baicalein.

FIG.8 shows the Gas Chromatogram (GC) of the extracts of Flos Lonicerae and Fructus Forsythiae, wherein the relative time (t_R) of peak is about 11.907, 14.12 and 22.21
30 min respectively. (Not Shown)

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a composition comprising effective amount of extracts from *Flos Lonicerae Fructus Forsythiae* and *Radix Scutellariae*. This invention also provides an antiviral and antibacterial pharmaceutical composition comprising effective amount of *Flos Lonicerae Fructus Forsythiae* and *Radix Scutellariae*. This invention provides the above compositions, wherein the ratio of is 1:2:1. The ratio of the plants are adjustable and could have similar efficacious effect in treating different diseases.

This invention also provides a method for identifying the composition of *Flos Lonicerae* raw material, which comprises the steps of: a) using Chlorogenic acid as the standard and using *Flos Lonicerae* raw material as a sample; b) preparing the sample solution of *Flos Lonicerae* raw material further comprising the steps of: i) Taking some *Flos Lonicerae*, rub it into powder and then pass the 40 item of bolt; ii) weighing exactly 187.5 mg and put it into the centrifuge tube; adding 4ml of methanol/water to a volute mixer and mix for 1 min. Then ultrasonically vibrate and extract for 15 min, centrifuge it, and take the upper solution; iii) adding 4ml of methanol/water and ultrasonically vibrate and extract the residue for another 15min. Centrifuge and take the upper clear solution; iv) Washing the residue with 1.5ml of methanol/water and combine it with the upper clear solution. Scale the sample solution in a 10ml of flask. v) filtering it with 0.45µm filtration membrane before giving sample; c) performing the Fingerprint Chromatogram (HPLC-FPS) of *Flos Lonicerae* raw material under the following conditions:

Conditions of Raw Material HPLC-FPS

Chromato-	Protectin	Floating	Tempera-	Inspector	Injection	Run
-----------	-----------	----------	----------	-----------	-----------	-----

graphic Column	g Column	Phase	ture		Volum	Time (min)
Inertial ODS-3,5µm 4.6mm*250mm	phenomene x C18 (ODS), 4mm*3mmID	1% acetic acid solution	room tempera- ture	PDA210~400nm of wavelength scan	5.00µl	35

d) Calculate the value in accordance with the following calculating formula:

$$Cx = C1 + (C2 - C1) * (Ax - A1) / (A2 - A1)$$

5 C1 and C2: quantities of the standard.

A1 and A2: peak areas of the standard.

Cx and Ax: quantity and peak area of the sample.

e) The HPLC-FPS of Flos Lonicerae raw material:

10 The amounts of peaks are 8 at low limit and 11 at high limit, when the peak area is over 2.0×10^6 .

This invention also provides a method for identifying with HPLC-FPS the composition of Fructus Forsythiae raw material, which further comprises the steps of: a) Using
15 Phillyrin as the standard, and use the Chinese Fructus Forsythiae raw material as the sample; b) weighing exactly 375mg of the powder of Fructus Forsythiae raw material, and prepare the sample solution further comprising the same steps as described above; c)
20 performing the HPLC-FPS of Fructus Forsythiae raw material, under the conditions as described above; d) calculating the value of HPLC-FPS of Fructus Forsythiae raw material with the formula as decribed above; e) the HPLC-FPS of Fructus Forsythiae raw material:

25 The amounts of peaks are 11 at low limit and 14 at high limit, when the peak area is over 2.0×10^6 .

This invention provides a method for identifying with HPLC-FPS the composition of Radix Scutellariae raw

material, which further comprises the steps of: a) using Baicalin as the standard and use the Chinese Radix Scutellariae as the sample; b) weighing exactly 187mg of the powder of Radix Scutellariae raw material and prepare
5 the sample solution further comprising the same steps as described above; c) performing the HPLC-FPS of Radix Scutellariae raw material, under the conditions described above; d) calculating the value of HPLC-FPS of Radix Scutellariae's raw material with the formula as described
10 above; e) the HPLC-FPS of Radix Scutellariae's raw material: The amounts of peaks are 22 at low limit and 25 at high limit, when the peak area is over 2.0×10^6 .

This invention provides a method for identifying the
15 composition of the drug substance of Flos Lonicerae and Fructus Forsythiae, which further comprises the steps of:
a) using the Chlorogenic acid and Phillyrin respectively as standards, and the drug substance of Flos Lonicerae and Fructus Forsythiae as a sample; b) preparing the sample
20 solution of the drug substance comprising the steps of:
i) taking some Flos Lonicerae and Fructus Forsythiae, grind them into powder and then pass the 40 item of bolt;
ii) weighing 107.5 mg of the powder and put it into an centrifuge tube; iii) adding 4ml of methanol/water to a
25 volute mixer and mix for 1 min; iv) Shaking the extracts ultrasonically for 15 min, centrifuge and take the upper solution; v) adding 4ml of methanol/water and ultrasonically vibrate and extract the residue for another 15min, centrifuge and take the upper clear solution; vi)
30 washing the residue with 1.5ml of methanol/water and combine it with the upper clear solution, scaling the sample solution in a 10ml of flask; vii) filtering it with 0.45 μ m filtration membrane before giving sample;
c) performing the HPLC-FPS of the drug substance of Flos

Lonicerae and Fructus Forsythiae, under the following conditions:

Conditions of HPLC-FPS of Drug Substance

Chromato- graphic Column	Protectin g Column	Floating Phase	Tempera -ture	Inspector	Injectio n Volum	Run Time (min)
Inertsil ODS-3,5 μ m 4.6mm*250mm	phenomene x C18(ODS), 4mm*3mmID	1% acetic acid solution	room tempera -ture	PDA210~400n m whole wavelength scan	20.00 μ l	35

5

d) The HPLC-FPS of the drug substance of Flos Lonicerae and Fructus Forsythiae: the amounts of peaks are 18 at low limit and 23 at high limit, when the peak area is over 2.0×10^6 .

10

This invention provides a method for identifying with HPLC-FPS the composition of the drug substance of Radix Scutellariae, which further comprises the steps of: a) using Baicalin as the standard solution and use the drug substance of Radix Scutellariae as the sample solution; b) weighing exactly 20 mg of the powder of Radix Scutellariae and prepare the sample solution of the drug substance, further comprising the same steps as described above; C) performing the HPLC-FPS of the drug substance of Radix Scutellariae, under the conditions described above; d) the HPLC-FPS of the drug substance of Radix Scutellariae: The amounts of peaks are 4 at low limit and 5 at high limit, when the peak area is over 2.0×10^6 .

25

This invention provides a method for identifying with HPLC-FPS the composition of the drug product, which further comprises the steps of: a) using Chlorogenic acid,

Phillyrin and Baicalin as the standards and using the drug product with the batch number 00912 as the sample; b) weighing exactly 200 mg of the powder of drug product and prepare the sample solution of the drug substance, 5 further comprising the steps described above; c) performing the HPLC-FPS of the drug substance of drug product, under the conditions described above; d) the HPLC-FPS of the drug substance of drug product: the amounts of peaks are 27 at low limit and 30 at high limit, when 10 the peak area is over 1.95×10^6 .

This invention provides a method for preparing a pharmaceutical composition comprising an extracts of Fructus Forsythiae and Flos Lonicerae. In an embodiment, 15 the composition of Fructus Forsythiae and Flos Lonicerae was prepared with CO₂ supercritical fluid extraction under the control of homogeneous design.

This invention provides a method for preparation a 20 composition comprising Fructus Forsythiae and Flos Lonicerae comprising the steps of: (a) preparing the extract with CO₂ supercritical fluid extraction with or without aqueous alcohol under the following conditions: 8.0-14.0MP of pressure, at 32-40°C of temperature for 1-3 25 hours; (b) breaking the materials into 20-60 mesh of reduction ratio; and (c) obtaining a 0.1-1% of extract rate.

This invention provides a method for preparing the above 30 composition comprising extracts of Fructus Forsythiae and Flos Lonicerae comprising CO₂ supercritical fluid extraction containing the amount of aqueous alcohol entrainment, which is equal to the amount of 10%-90% CO₂.

This invention provides a method for embedding with CO₂ supercritical fluid extraction the supercritical extract of *Fructus Forsythiae* and *Flos Lonicerae*, wherein the supercritical extract was embedded with saturated solution of β -cyclodextrin. In an embodiment, the embedding rate is about 60%.

This invention provides a method for preparing the a composition comprising extracts of *Fructus Forsythiae* and *Flos Lonicerae* comprising the steps of: (a) embedding the supercritical extract of *Fructus Forsythiae* and *Flos Lonicerae* with saturated solution of β -cyclodextrin; (b) determinating the benzine content; and (c) granulating with solid dispersion technique. In an embodiment, the active ingredients of the supercritical extracts consisted of β -pinene, sabinene, α -pinene and linalool.

In a separate embodiment, the extract of *Fructus Forsythiae* and *Flos Lonicerae* with subboiling aqueous are extracted under the following conditions: 80-95°C of temperature and 1-3 hours of time.

This invention provides a method for purifying the sample solution with flocculating process, wherein the process was performed under the following conditions: the amount of flocculant is about 0.5g-3.5g/100g of raw material; when the flocculant is added the specific gravity of the sample solution is 1.01-1.35. The temperature of the sample solution with the flocculant is 35-80°C. Concentration of aqueous alcohol is about 70-95%. The specific gravity of the sample solution is 1.1-1.3, when the aqueous alcohol is added.

This invention provides a method for determining with chromatography the content of Chlorogenic Acid in the Flos Lonicerae raw material comprising the steps of: a) using Chlorogenic acid as the standard solution and use Flos raw material as the sample solution; b) preparing the sample solution, further comprising the steps of: i) taking some Flos Lonicerae raw material, rub it into powder and pass the 40 item of bolt; ii) weighing up exactly 134mg of the powder and put it into the centrifuge tube; iii) adding 4ml of methanol/water to a volute mixer and mix for 1 minute; iv) Shaking the mixture and the extract ultrasonically 1 min., and then centrifuge it; v) taking the upper clear solution and add 4ml of methanol/water to the residue and ultrasonic for 15 min, centrifuge it again; vi) washing the residue with 1.5ml of methanol/water and combine it with the upper clear solution. Scale the sample solution in a 10ml of flask; vii) filtering with 0.45um of filtration membrane before giving sample; c) performing the HPLC of Chlorogenic Acid content of Flos Lonicerae raw material under the condition:

Conditions of HPLC-FPS of Raw Material Content

Chromato-graphic Column	Protectin g Column	Floating Phase	Tempera- ture	Velocity of flow	Testing Wavelengt h	Run Time (min)
Inertsil ODS-3,5µm 4.6mm*250mm	phenomene x C18(ODS) 4mm*3mmID	methanol: water=25:75 (contains 2% acetic acid)	room tempera- ture	1ml/min	280nm	35

d) Content of Chlorogenic Acid of Flos Lonicerae raw material:

Example: i) 1.85%; ii) 2.34%; iii) 1.51%. The result of the content is about 1.05%-1.68%.

This invention provides a method for determining with chromatography the content of Phillyrin of Fructus Forsythiae raw material comprising the steps of: a) using
5 Phillyrin as the standard solution and use Fructus Forsythiae raw material as the sample solution; b) taking 1.072g of the powder of Fructus Forsythiae and prepare the sample solution comprising the steps as describe above; c) performing the HPLC of Fructus Forsythiae raw material
10 under the following conditions:

Floating Phase: acetonitrile:water = 28:72; d)

Content of Phillyrin of Fructus Forsythiae raw material: Example: i) 0.21%; ii) 0.27%; iii) 0.17%. The result of the content is about: 0.10%-0.40%.

15

This invention provides a method for determining with chromatography the content of Baicalin of Radix Scutellariae raw material comprising the steps of: a) using Baicalin as a standard sample purchased from the Drug &
20 Biological Product Test Agency and use Radix Scutellariae raw material as a sample; b) taking 100mg of the powder of Radix Scutellariae and prepare the sample solution comprising the steps described above; c) performing the HPLC of Radix Scutellariae raw material under the
25 following conditions: Floating Phase: methanol: water (contains 2% acetic acid); and d) content of Baicalin of Radix Scutellariae raw material: Example: i) 4.21%; ii) 4.87%; iii) 3.81%. The result of the content is about 3.01%-4.47%.

30

This invention provides a method for determining with chromatography the Chlorogenic Acid content of drug substance of Fructus Forsythiae and Flos Lonicerae comprising the steps of: a) using the drug substance of

Fructus Forsythiae and Flos Lonicerae as a sample; b) preparing the sample solution further comprising the steps of: i) weighing exactly 170.5mg of the powder of drug substance of Flos Lonicerae and Fructus Forsythiae, and
5 put it into the centrifuge tube; ii) adding 4ml of methanol/water into a voluted mixer for 1 min; iii) Ultrasonically vibrate for 15 min, centrifuge and take the upper clear solution and ultrasonically vibrate the residue for another 15min; iv) washing the residue
10 with 4ml of methanol/water and combine it with the upper clear solution, scaling the sample solution in a 10ml of flask; vi) filtering it with the 0.45um of filtration membrane before giving sample; c) calculating Chlorogenic Acid content of the sample according to the above-
15 described formula and d) determining Chlorogenic Acid content of the drug substance: i) 2.52%; ii) 2.93%; iii) 2.15%. The result of Chlorogenic Acid content is about 1.00%-3.30%.

20 This invention provides a method for determining with chromatography the content of Phillyrin of the drug substance of Fructus Forsythiae and Flos Lonicerae comprising the steps of: a) weighing exactly 292mg of the drug substance of Fructus Forsythiae and Flos
25 Lonicerae; b) preparing the sample solution of extracts of Fructus Forsythiae and Flos Lonicerae, further comprising above steps; c) calculating Phillyrin content of the sample according to the same formula used in claim 1 and d) determining Phillyrin content of the
30 drug substance: i) 0.66%; ii) 0.59%; iii) 0.75%; The result of Phillyrin content is about 0.2%-0.5%.

This invention provides a method to determine by chromatography the content of Baicalin in the drug

substance of Radix Scutellariae comprising the steps of:

- a) weighing exactly 10mg of the drug substance of Radix Scutellariae; b) preparing the sample solution of the drug substance of Radix Scutellariae, further comprising the above-described steps; c) calculating Baicalin content of the sample according to the above-described formula; d) determine Baicalin content of the drug substance: i) 93.4%; ii) 92.2%; iii) 91.3%; The result of Baicalin content is about: 90.01%-93.40%.

10

- This invention provides a method for determining with chromatography the content of supercritical extract from of Fructus Forsythiae and Flos Lonicerae, comprising the steps of: a) determining the relative content under the following conditions: i) Gas Chromatographic: SE-54 elastic quartz capacity. Chromatographic column with a 30-meter length and a 0.32mm inner diameter. Gasification room temperature of 250°C. Column temperature ranges from 50-230°C rising 4°C/min controlled by procedure. ii) Gas carried to be Nitrogen with pre-column pressure of 0.7kg/cm; iii) Column vollumn of 2ml/min, giving sample quality of 0.4ul. Testing machine FID. b) content of supercritical extract of Fructus Forsythiae and Flos Lonicerae: i) Contrast with the standard sample when $t_R=8.551\text{min}$, β -pinene can be obtained. When $t_R=12.926\text{min}$, linalool can be obtained. The absolute peak area is about 766933. ii) Contrast with the standard sample when $t_R=8.575\text{min}$, β -pinene can be obtained. When $t_R=12.919\text{min}$, linalool can be obtained. The absolute peak area is about 1138138. iii) Contrast with the standard sample when $t_R=8.539\text{min}$, β -pinene can be obtained. When $t_R=12.930\text{min}$, linalool can be obtained. The absolute peak area is about 906224. c) GC-Chromatograph is given in Figure 8.

This invention provides a method for determining with GC-MS the supercritical extract of *Fructus Forsythiae* and *Flos Lonicerae*.

- 5 This invention provides a method for determining with GC-MS, wherein the values of GC-MS of the supercritical extract were shown in the following examples: β -pinene should be obtained at 8.551 min of RT (Retention Time). Linalool should be obtained at 12.926 min of RT. The
10 absolute peak area is about 766933. β -pinene should be obtained at 8.575 min of RT. Linalool should be obtained at 12.919min of RT. The absolute peak area is about 1138138. β -pinene should be obtained at 8.539 min of RT. Linalool should be obtained at 12.930 min of RT. The
15 absolute peak area is about 906224.

- This invention provides a formula of raw materials of the drug product comprising 1875g of *Flos Lonicerae*, 3750g of
20 *Fructus Forsythiae* and about 1875g of *Radix Scutellariae*.

- This invention also provides an intermediate formula of the drug product, wherein the subject drug substances are presented in the following amounts: about 90-180g of soft
25 extract of *Flos Lonicerae* and *Fructus Forsythiae*, 10-60g of supercritical extract of *Flos Lonicerae* and *Fructus Forsythiae*, 30-50g of *Radix Scutellariae* extract and 23-125g of excipients.

- 30 This invention provides a composition for preparing the drug product, wherein said constituents are presented in the following range: about 0.01 percent to about 99.99 percent of effective constituents, and about 99.99 percent to 0.01 percent of medical excipients.

This invention provides a composition, wherein said constituents are presented in the following formula: about 10 percent to 100 percent of *Flos Lonicerae*, 10 percent to 5 100 percent of *Fructus Forsythiae*, and 10 percent to 100 percent of *Radix Scutellariae*. In an embodiment, the constituents are further composed of about 1.3 percent to 1.6 percent of Chlorogenic acid, 0.2 percent to 0.3 percent of Phillyrin and about 14.1 percent to 15.3 10 percent of Baicalin.

This invention provides a composition for inhibition of herpes I virus and herpes II virus comprising three herbal materials: *Radix Scutellariae*, *Fructus Forsythiae* and *Flos* 15 *Lonicerae*.

EXPERIMENTAL DETAILS

Example 1

Preparation Techniques

20 This invention provides a unique formula of raw material for the composition of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae*, wherein the formula comprises 1875g of *Flos Lonicerae*, 3750g of *Fructus Forsythiae* and 1875g of *Radix Scutellariae*.

25

This invention provides an intermediate formula for the composition of drug substances. The formula comprises a range of 90-180g extract of *Fructus Forsythiae* and *Flos* *Lonicerae*, a range of 30-50g extract of *Radix* 30 *Scutellariae*, a range of 10-60g supercritical extract of *Fructus Forsythiae* and *Flos Lonicerae* and a range of 23-125g of excipients.

This invention provides a composition further comprising supercritical extracts which includes β -pinene, sabinene, α -pinene, linalool.

- 5 This invention provides a method for preparing an extract of the *Radix Scutellariae*. The extraction includes the following steps: (a) Cut the raw material of *Radix Scutellariae* into small piece; (b) Put the small pieces through a process of reflux in ten times the volume of
10 water; (c) Concentrate the soft extract at 80°C; (d) Adjust the value of PH to 1.0-2.0 with 2mol/L of chlorhydric acid; (e) Elute the residue to a 5.0 of PH value with water, and then eluting it to a 7.0 of PH value with 70% aqueous alcohol; (f) Dry it at lower temperature; (g)
15 Produce an extract of *Radix Scutellariae*.

- This invention provides a method for preparing an extract of *Fructus Forsythiae* and *Flos Lonicerae* with sub-boiling aqueous extraction. The method comprises the following
20 steps: (a) Take the decoction dregs of *Fructus Forsythiae* and *Flos Lonicerae* after extracted with CO₂ supercritical fluid and add 10 times of water; (b) Put the mixture into a process of agitation and dynamic extraction for 2 hours and filtration; (c) Concentrate the decoction to about
25 1.03 of relative density at 25°C; (d) Cool the filtrate and add flocculating agent; (e) filtration and concentrate the flocculation solution to about 1.1 to 1.2 of relative density at 25°C. (f) Add 80% of aqueous alcohol solution to sedimentation; (g) After concentrating, obtain
30 the aqueous extract of *Fructus Forsythiae* and *Flos Lonicerae*.

This invention provides a method of flocculation and alcohol sedimentation for the sub-boiling aqueous extracts

- of *Fructus Forsythiae* and *Flos Lonicerae*, wherein the method was conducted under the following conditions: (a) the ratio of decoction: add 0.5g-3.5g of flocculating agent to 100g of raw material; (b) Filtrate the decoction to about 1.01 to 1.35 of relative density; (c) Keep the temperature at 35-80°C. (d) Add a 70-95% of alcohol concentration; (d) Keep a 1.1-1.3 of specific gravity while alcohol is added.
- 10 This invention provides a method for preparing an extract of *Fructus Forsythiae* and *Flos Lonicerae* with CO₂ supercritical fluid extraction comprising the following steps:
- I) CO₂ supercritical fluid extraction without entrainment: (a)
- 15 Break the mixture of *Fructus Forsythiae* and *Flos Lonicerae*; (b) Put the broken mixture through a process of extraction in an extractor under the 8.0-14.0MP of pressure; (c) Produce the extract of *Fructus Forsythiae* and *Flos Lonicerae*.
- 20 II) CO₂ supercritical fluid extraction with entrainment: (a)
- Break the mixture of *Fructus Forsythiae* and *Flos Lonicerae*; (b) Put the broken mixture through a extraction process under 8.0-14.0MP of pressure; (c) Add 90-95% aqueous alcohol, equal to a 10%-90% the volume of CO₂, to the extractor; (d) Obtain the extract of *Fructus Forsythiae* and *Flos Lonicerae*.
- 25
- 30 This invention provides a method for embedding the CO₂ supercritical extracts of *Fructus Forsythiae* and *Flos Lonicerae* with saturated aqueous solution of β -cyclodextrin (β -CD). Wherein the method comprises the following steps:

- (a) Prepare the inclusion compound: (i) take respectively 6.0g, 8.0g, 10.0g of β -CD and put it into a flask with 150ml of volume. (ii) Add the β -CD respectively to distilled water with a ratio of 1:6. (iii) Heat the liquid to dissolution, and then decrease the temperature. (iv) Put the flask on a magnetic agitator. (v) Slowly inject 1 ml of Benzin to the β -CD solution with a 1 ml of injector. (vi) Agitate and keep it in cold storage. (vii) Filter and collect the inclusion compound, and then dry the solution of inclusion compound to the powder at 60°C for 2 hours;
- (b) Determine the content of benzin of inclusion compound, wherein the method supposed to comprises the following steps: (i) Take the inclusion compound and put it into a 500 ml of flask. (ii) Add 200 ml of distilled water and connect the flask with an extractor of benzin, according to the operation procedure in the Appendix 6 of Chinese Pharmacopeia, 1995. (iii) Record the content of benzin; and
- (c) Determine the black recovery rate of benzin

This invention provides a method for embedding the extract of *Fructus Forsythiae* and *Flos Lonicerae* with about a 60% of the embedding rate.

25

This invention provides a method for preparing the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae*. Wherein the said method is consisted of: (a) Draw up a formula of raw materials, including *Flos Lonicerae* to *Fructus Forsythiae* to *Radix Scutellariae* (1:2:1); (b) Prepare the extract of *Radix Scutellariae*; (c) Prepare the extracts of *Fructus Forsythiae* and *Flos Lonicerae* with sub-boiling aqueous and with CO₂ supercritical fluid respectively; (d) Embed the CO₂

supercritical extracts of *Fructus Forsythiae* and *Flos Lonicerae* with saturated aqueous solution of β -cyclodextrin; (e) Determine the benzene content in inclusion compound; (f) The extract of *Radix Scutellariae* and the carrier were subjected to a process of granulating with solid dispersion technique.

This invention provides a composition comprising 0.01% to 99.99% of effective constituents and 99.99% to 0.01% of medical dressing.

FORMULA EXAMPLES:

Example 1

To obtain a 3% of extract rate of the drug substance, the formula is as follows: 90g of soft extract of *Flos Lonicerae* and *Fructus Forsythiae*, 30g of extract of *Radix Scutellariae*, 15g of supercritical extract of *Fructus Forsythiae* and *Flos Lonicerae*, and 24g of excipients.

Example 2

To obtain a 4% of extract rate of the drug substance, the formula is as follows: 120g of soft extract of *Flos Lonicerae* and *Fructus Forsythiae*, 30g of extract of *Radix Scutellariae*, 15g of supercritical extract of *Fructus Forsythiae* and *Flos Lonicerae*, and 29g of excipients.

Example 3

To obtain 5% of extract rate of the drug substance, the formula is as follows: 150g of soft extract of *Flos Lonicerae* and *Fructus Forsythiae*, 30g of extract of *Radix*

Scutellariae, 15g of supercritical extract of *Flos Lonicerae* and *Fructus Forsythiae*, and 34g of excipients.

Example 4

- 5 To obtain a 6% of extract rate of the drug substance, the formula is as follows: 180g of soft extract of *Flos Lonicerae* and *Fructus Forsythiae*, 30g of extract of *Radix Scutellariae*, 15g of supercritical extract of *Fructus Forsythiae* and *Flos Lonicerae*, and 40g of excipients.

10

Supercritical Fluid Extraction Technology

1. Fluid Extraction

- Carbon dioxide is considered the best gas medium to be used in this experiment. The CO₂ has the property of
15 allowing quick dissolution of the three herbs used in this process to easily obtain the components needed for the invention. Therefore, the CO₂ extracting technology has been adapted in order to obtain and separate the effective ingredients of the raw materials used in the experiment.

20

2. Carrying solvent Extraction

- Some carrying solvents of the CO₂, such as ethanol, can help in the extraction of the components found in the raw materials used for this invention. Ethanol: CO₂ = 0.1-
25 0.9:1.

3. Main parameters

A. Pressure

- Supercritical fluid can be pressed greatly. When the
30 temperature is constant, the density of the supercritical fluid increases with pressure and the ingredient solubility in fluid is improved simultaneously.

B. Temperature

If pressure is constant, the extracting effect is heightened by high temperature.

C. Time

Usually, the longer the time, the more extract would be
 5 obtained from the process. Still, it is possible that some unnecessary matters could be extracted out and then more CO₂ is consumed.

D. Materials

The higher the reduction ratio (refinement of the powder)
 10 the more it can be used to promote the diffusion of the materials. The positive effect of having a high reduction ratio can be damaging if the powder is too thin.

E. Carrying solvent

Usually, carrying solvents are more useful in order to get
 15 more substance.

4. Experiment

Table 1 Materials

Name	Producing Area	Seller	Appraisal
<i>Radix Scutellariae</i>			
<i>Flos Lonicerae</i>	Shandong	ShanghaiHuaYu	Eligible
<i>Fructus Forsythiae</i>	Henan	ShanghaiHuaYu	
CO ₂	Shanghai	Wujing Chem	Plant Food Grade

20 Table 2 Supercritical Extraction Equipment

Sepecification	Producer
200ml	Nova Co. Switzerland
20L	Jiangsu, China
100L	Shanghai, China

C. Experiment Process

The sack, including the smashed *Flos Lonicerae* and the *Fructus Forsythiae* were put into the extractor. The
5 solution was kept under the following conditions: 8.0-14.0MP of pressure and 32-40°C of temperature for one hour. The extracts were analyzed with GC.

5. Conditions

10 Herbs *Flos Lonicerae* and *Fructus Forsythiae* were processed by supercritical CO₂ extraction under the following conditions: 8.0-14.0MP of pressure and 32-40°C of temperature for one hour. GC tested the product to be steady. Physiology research proved its properties as an
15 anti-virus. The effectiveness of the final product was improved with the use of the new technique of extraction.

Flocculating Test

The separation technology is the key to raise the level of traditional Chinese medicine. The refining method usually
20 is ethanol subsiding and the flocculating method.

1. The methods and principles of refining traditional Chinese medicine


The technology of ethanol subsiding is usually used to
25 refine Chinese medicine preparations. One of the principles of the ethanol subsiding is that some effective components of traditional Chinese medicines can be dissolved not only in water but also in ethanol. The unsolvable substances in ethanol can be subsided in a
30 mixed solution of water and ethanol in order to refine the product and improved its quality.

In the Flocculating process, a flocculating agent is used to refine traditional Chinese medicine. An example of a

flocculating agent is the Chitosan, which is added to the extracting solution. Colloid pellets were cleared away in an absorbing matter, such as protein and mucilage, and then were filtrated to refine the solution. The extracting solution of the traditional Chinese medicine has many components, such as polymer, mucus, protein, and starch. When Chitosan is added, big pellets were cleared away by the absorbing function of the bridge and the electric neutralization. This technology has many advantages: fewer raw materials are used, the equipment is simple and production costs are lower. The speed of flocculating is fast and less production time is needed.

2. Properties of flocculating agent

Chitosan is a kind of linear ploycarbohydrate, a good flocculating agent of natural polyme instead of the synthetic one. Its chemical name is poly [β -(1,4)-2-amino-2deoxy-D-glucopyranose]. Chitosan is a natural polymer that is safe for consumption. The process of preparing shell material to render Chitosan is presented in Below






Figure 1. Flow chart for Chitosan preparation

10

Preparation of the Drug Product

The mixed material of *Flos Lonicerae* and *Fructus Forsythiae* were extracted with ten times of the volume of water. The decoction was filtrated and the extracting
 15 solution was concentrated and flocculated with Chitosan. Ethanol was added to this concentrated solution. The ethanol solution was filtrated and evaporated as well. The method was designed as follows:

20 1. Well-distributed design: (see Table 3)

Table 3 Test of well-distributed design

No	Extracting Temperature (°C)	Time (h)	Flocculatin g agent (g/100g)	Flocculating Temperature (°C)	Concentra- tion (ml/g material)
1	75.0	1.5	1.5	65.0	3.5
2	75.0	2.0	2.5	50.0	3.5
3	75.0	2.5	3.5	35.0	3.5
4	80.0	3.0	0.5	80.0	2.5
5	80.0	1.5	2.5	50.0	2.5
6	80.0	2.0	3.5	35.0	2.5
7	85.0	2.5	0.5	80.0	1.5
8	85.0	3.0	1.5	65.0	1.5
9	85.0	1.5	3.5	35.0	1.5
10	90.0	2.0	0.5	80.0	0.5

11	90.0	2.5	1.5	65.0	0.5
12	90.0	3.0	2.5	50.0	0.5

Table 4 Results of well-distributed

No	ratio of product (%)	Percent of Chlorogenic acid (%)	clearness of solution
1	17.5	1.19	+++.
2	17	1.18	++
3	17	1.09	+
4	18.5	1.20	++++
5	17.5	1.10	+
6	17	1.26	+
7	16.5	1.21	++++
8	17	1.29	-
9	17	1.34	-
10	13	1.41	-
11	13	1.40	+
12	13	1.35	-

5

2. The effect of extracting temperature

Table 5 Effect of extracting temperature

Time (h)	Temperature (°C)	Chlorogenic acid (mg/ml)
2	80	0.380
2	85	0.390
2	90	0.409
2	95	0.362
3	95	0.334
2.5	90	0.392

The extracting temperature affected the amount of Chromogenic acid. The best condition to extract the material is at 90°C for two hours.

5 3. The effect of flocculating agent

Table 6 Effect of flocculating agent

Flocculating agent (g/100material)	Clearness of solution	Precipitate form
0.5	Muddy	Fine
1.0	Muddy	Fine
1.5	Clear	Fine
2.0	Clear	Thick
2.5	Clear	Fine
3.0	Muddy	Fine
3.5	Muddy	Fine

The amount of flocculating agent mainly affects the clearness of the solution. When the amount of flocculating agent varies, for example to a 0.5g/100g or 3.5g/100g of raw material, the solution could become muddy. While the amount of flocculating agent is suitable, the solution is clear. The reason is because the flocculating function is absorbing the bridge and the electric neutralization. If the amount of flocculating agent is reduced, the flocculating pellets cannot be formed between colloid. If the amount of flocculating agent is increased, then the Chitosan surrounds the colloid and the possibility of absorbing the bridge is lost, so the colloid is stable. When Chitosan covers a part of the colloid surface is possible to obtain the best results from flocculating. So the scope of flocculating agent is 1.5-2.5g/100g material.

4. The effect of flocculating temperature

The flocculating temperature mainly affects the clearness of the solution and precipitates its form. When the temperature is higher, the solution is muddy, but the pellet is thick. When the temperature is lower, the solution is clear, but the pellet is thinner. Therefore, the most appropriate temperature to be used in this experiment is 50°C.

Table 7 Effect of Flocculating Temperature

Temperature (°C)	Clearness of solution	Precipitate form
20	Clear	Fine
30	Clear	Fine
40	Clear	Fine
50	Clear	Thick
60	Clear	Thick
70	Muddy	Thicker
80	Muddy	Thicker

10

5. The effect of the solution concentration

The concentration affects mainly the ratio of product. With the increasing of the concentration, the ratio of product is lower. For example, when the ratio of material and solution is equal to 2:1(g/ml), the obtained ratio is the lowest. At the more concentrated solution, the Chitosan agent is more difficult to disperse in the decoction process and it is also easier to coagulate into small particles.

20

6. The across test

The amount of Chitosan, the quality and ratio of product and the effects of the extracting temperature were studied based on well-distributed tests. In order to purify and reduce the ratio of product, further studies were made of

25

the amount and concentration of Chitosan, and the concentration of ethanol on the quality of product.

Table 8 Across Design for the technique of drug product

NO.	Flocculant g/100g	The 2 nd concen- tration(ml/100g)	Concentration of ethanol(%)	Material/solu- -tion (G/ml)
1	1.5	10	90	1:0.5
2	1.5	15	80	1:0.8
3	1.5	20	70	1:1.0
4	2.0	10	80	1:1.0
5	2.0	15	70	1:0.5
6	2.0	20	90	1:0.8
7	2.5	10	70	1:0.8
8	2.5	15	90	1:1.0
9	2.5	20	80	1:0.5

5

During the trial period, the method of flocculating was combined with ethanol subsiding. Most of the components, such as proteins and carbohydrates, had been removed but other components were retained by flocculation. Most of the polysaccharides and the Chitosan had been removed by ethanol subsiding.

10

Table 9 The result of Across Design for the technique of drug product

15

No	Flocculant g/100g	The concentra- tion (ml)	ethanol (%)	Material solution (g:ml)	ratio of product (%)	percentof Chlorogenic acid(%)
1	1.5	10	90	1:0.5	4.25	1.88
2	1.5	15	80	1:0.8	5.25	0.86
3	1.5	20	70	1:1.0	9.25	1.38
4	2.0	10	80	1:1.0	4.13	1.65
5	2.0	15	70	1:0.5	8.50	1.87

6	2.0	20	90	1:0.8	5.88	1.63
7	2.5	10	70	1:0.8	4.00	1.62
8	2.5	15	90	1:1.0	2.63	1.34
9	2.5	20	80	1:0.5	6.13	1.61

With the increase in the amount of Chitosan used in the second concentration of solution and the concentration of ethanol, the ratio of product decreased. The process of refining traditional Chinese medicine consists in having 100g material extracted in ten times the amount of water at 90°C for 2 hours. After being filtrated and concentrated to 80 ml (the density is 1.124), 133 ml 1.5%, the flocculating agent was added. Stirred for 5 minutes, centrifugalized and concentrated to 16 ml (the density is 1.26). 95% ethanol was added until the percentage reached 85. Once filtrated and concentrated, the ratio of product was 4-5%. The percent of Chlorogenic acid was 1.55%.

EXAMPLE 2

Pharmacological Studies

The pharmaceutical compositions comprising the extract of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* described in this invention are effective for the inhibition of influenza virus and parainfluenza virus, herpes I virus and herpes II virus.

1. Anti-virus Test

A. Anti-virus test in vivo

The extract of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae*, both with supercritical fluid extraction and sub boiling aqueous extraction, were used as test drugs. A chemical drug known as Ribavirin, Batch No. 980606, was positively controlled with the extract mentioned above.

Influenza virus A3, parainfluenza virus I (HVJ0), herpes I virus, herpes II virus (HSV-I, II), and Hep-2 cells (human epithermoid carcinoma) were used as test materials.

5

In the invention, the cytotoxic test was conducted with clonal Hep-2 cells of human epithermoid carcinoma. The decoction was diluted with the culture solution of Eagles in multiple proportions. The culture solution of Hep-2 cell cultured in 96 pores of microculture plate was discharged and 100ul of a different dilution was added to the decoction. The normal cells were controlled with the cultured cells. The cultured plate was laid in a CO₂ incubator at 37°C for 3 days. The extract toxicity for the cells was delimited in accordance with the minidilution titer without the degeneration of cells. 50% of the toxic concentration (CC₅₀) was calculated with the method of Reed-Mucnch.

20 A total of 50ul of different viral solution was inoculated to the cell plate and was put into CO₂ incubator for absorption. 100ul decoction of different dilution was added to the inoculated plate and observed in CO₂ incubator at 37°C for 3 days. The test group was compared to the virus auto-control group, to the positive control group with Ribavirin, and to the normal cell control group.

30 The result of the test showed that there was a difference for anti-virus effect between different sites of extraction (Table 10). The extracts of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* with supercritical fluid extraction had a significant inhibition for influenza virus and parainfluenza virus. The extracts of *Flos Lonicerae*, *Fructus Forsythiae* and

Radix Scutellariae with sub-boiling aqueous extraction had also a certain inhibition degree for influenza virus, herpes I virus and herpes II virus (HSV-I, II). (Table 11)

Table 10 Effect for anti-virus in different sites of extraction

Virus	Ribavirin	EC ₅₀ (crude drug µg /ml)	
	(125µg/ml)	Supercritical Extraction Site	Sub-boiling Aqueous Extraction Site
A ₃	+	83.93(6.7)	236.6(9.4)
HVJ	+	167.5(3.4)	-
HSV-I	+	-	561.2(4.0)
HSV-II	+	-	472.1(4.7)

Table 11 Inhibitory effect of different drug products on cytopathy induced by virus

Virus	Ribavirin (125µg/ml)	EC ₅₀ (crude drug µg /ml) (IT)			
		No.25	No.26	No.27	SHL tablet
A ₃	+	4.7(4.8)	4.7(4.8)	3.3(6.8)	4.7(4.8)
HVJ	+	4.7(4.8)	4.7(4.8)	3.3(6.8)	4.7(4.8)
RSV	+	11.1(2.0)	11.1(2.0)	6.7(3.4)	11.1(2.0)
HSV-I	+	-	11.1(2.0)	6.7(3.4)	-
HSV-II	+	-	11.1(2.0)	6.7(3.4)	-

Note: "+": effective, "-": ineffective

SHL (Shuanghuanglian) tablet is a previous product produced with different techniques.

No.25, 26 and 27 are the samples of drug product produced with new techniques.

5

B. Anti-virus test in vivo

Table 12 Effect of different drug products on Virus Pneumonia induced by influenza

Groups	Dosage (g/kg)	Mice (n)	Lung index ($\bar{X} \pm SD$)	Inhibitive rate(100%)	P value
Infection control	-	10	1.54 \pm 0.25		
Normal control	-	10	0.91 \pm 0.07		<0.01
Ribavirin	0.07	10	1.16 \pm 0.15	24.68	<0.01
SHL tablet	33.0	10	1.27 \pm 0.19	17.53	<0.05
	16.5	8	1.33 \pm 0.17	13.64	>0.05
No.25	33.0	10	1.33 \pm 0.13	13.64	<0.05
No.26	33.0	10	1.33 \pm 0.8	13.64	<0.05
	16.5	10	1.36 \pm 0.18	11.69	>0.05
No.27	33.0	10	1.25 \pm 0.21	18.83	<0.01
	16.5	8	1.32 \pm 0.20	14.28	<0.05

Note: SHL (Shuanghuanglian) tablet is a previous drug product produced with different techniques.

10

No.25, 26 and 27 were the samples of drug products produced with the new techniques.

15 2. Anti-anaphylaxis Test

A three-color guinea pig was used in the following experiment. The extracts of Flos Lonicerae, Fructus Forsythiae and Radix Scutellariae, both with supercritical fluid extraction and with subboiling aqueous extraction, were used as test drugs. Ebalin, an antihistamine, was used as the control drug.

20

The ileum of a guinea pig was taken and hung on a Magnus' bath. The basic contraction frequency of the ileum was recorded with the MacLab method. There was a total of four groups involved in this experiment: the histamine alone, the histamine plus Ebalin, the histamine plus the supercritical extract of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae*, and the histamine plus sub-boiling aqueous extract. The test curves were respectively recorded after the administration of the histamine and the other test drugs. The inhibitory rate and exciting rate were calculated with the following formula:

15

$$\text{Inhibitory/exciting rate(\%)} = \frac{\text{Normal mean wave amplitude} - \text{post-test mean wave amplitude}}{\text{Normal mean wave amplitude}} \times 100\%$$

20 The results of the test demonstrated that supercritical extract and sub-boiling aqueous extract, and the different products of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* had significant inhibition for ileum contraction induced by histamine. (Table 13, Table 14)

25

Table 13 Inhibitory effect of the different extracts on histamine in guinea pig

Group	Concentration (g/ml)	Inhibition/excitation(%)
Histamine	3.3×10^{-6}	271 ± 42
Histamine + Ebalin	$3.3 \times 10^{-6} + 1 \times 10^{-3}$	$181 \pm 32^{**}$
Histamine + supercritical	$3.3 \times 10^{-6} + 1 \times 10^{-3}$	$234 \pm 59^{*}$

supercritical

extract

Histamine + sub- $3.3 \times 10^{-6} + 1 \times 10^{-3}$ $203 \pm 96^*$

boiling aqueous

extract

Note: * $P < 0.05$, ** $P < 0.01$, in comparison with the control group

5 Table 14 Inhibitory effect of the different drug products on histamine in guinea pig

Group	Concentration (g/ml)	Inhibition/excitation (%)
Histamine	3.3×10^{-6}	235.29 ± 35.30
Histamine +Ebalin	$3.3 \times 10^{-6} + 1 \times 10^{-6}$	$133.81 \pm 40.55^{**}$
Histamine + No.21	$3.3 \times 10^{-6} + 1 \times 10^{-3}$	237.75 ± 52.08
Histamine + No.22	$3.3 \times 10^{-6} + 1 \times 10^{-3}$	181.45 ± 35.46
Histamine + No.23	$3.3 \times 10^{-6} + 1 \times 10^{-3}$	220.98 ± 46.39
Histamine + No.24	$3.3 \times 10^{-6} + 1 \times 10^{-3}$	$179.21 \pm 25.00^*$
Histamine + No.29	$3.3 \times 10^{-6} + 1 \times 10^{-3}$	229.93 ± 28.08

Note: * $P < 0.05$, ** $P < 0.01$, compared with control group;

No.21, 22, 23 and 24 are the samples of drug product, which are produced with new techniques.

10 No.29 is a drug product produced with previous techniques.

3. Anti-inflammation Test

3.1 Effect for Leukotaxis

Rats were used as test animals. The supercritical extract of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae*, was dissolved with dimethyl sulfoxide, 5 diluted with RPMI-1640 and used as the test drug.

The inhibitory effect of supercritical extract and sub-boiling aqueous extract for leukotaxis was observed in the test of rats through the following steps: 1) Preparing 10 10^9 /ml of leukocytic suspension. 2) Dissolving 4mg of agarose into 0.5ml of distilled water and cooling it to 37° C of temperature, and then mixing it with RPMI-1640. 3) Taking 0.1 ml of the solution of agarose and 0.1ml of leukocytic suspension. 4) Injecting the mixed solution of 15 leukocyte and agarose prepared above into a cultured plate of 96 pores, 2ul for each. 5) Dividing the test group in four groups with normal saline (NS), Chemitactic agent, Dimethyl sulfoxide (DMSO) and test drugs (three doses). 6) Determining the distance of leukocytic movement with 20 position finder under the microscope and calculating mobile area. 7) Analyzing the data with T test.

The result showed that the supercritical extract and sub-boiling aqueous extract of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* had a significant effect 25 in the inhibition for the leukotaxis. It suggested that the different extracts and the drug products of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* had also obvious inhibitory effect for inflammation. (Table 30 15, Table 16)

Table 15 Inhibitory effect of the different extracts on Leukotaxis

Group	Dosage (mg/ml)	Area of Leukocyte movement
-------	----------------	----------------------------

(mm ²)		
Normal Saline	--	17.0 ± 11.1
FMLP	5nM	229.2 ± 191.9#
DMSO		159.6 ± 127.1#
supercritical extract	1.0	128.6 ± 147.9
	0.1	22.8 ± 27.2∇
	0.01	18.2 ± 11.9∇
sub-boiling aqueous extract	1.0	27.5 ± 22.1*
	0.1	28.1 ± 25.6*
	0.01	11.9 ± 9.9 *

Note: DMSO: Dimethyl sulfoxide

P<0.05, in comparison with the Normal Saline group

* P<0.05, in comparison with the FMLP group

∇ P<0.05, in comparison with the DMSO group

5 Table 16 Inhibitory effect of the drug products with different technique on the Leukotaxis

Group	Dosage (mg/ml)	Area of Leukocyte movement (mm ²)
Normal Saline	--	2.08 ± 0.51
FMLP	5nM	7.89 ± 4.92#
Dimethyl sulfoxide		7.87 ± 4.12##
Normal Serum		7.71 ± 3.52##
No. 22	1.0	7.94 ± 2.74*
	0.1	7.06 ± 3.44*
	0.01	7.27 ± 2.62
No. 24	1.0	3.42 ± 1.9*
	0.1	5.3 ± 2.43
	0.01	6.01 ± 2.67
No. 29	1.0	6.14 ± 2.31
	0.1	6.84 ± 3.11

	0.01	6.08 ± 3.13
Drug-serum 22	40min	4.55 ± 1.55V
Drug-serum 22	80min	4.61 ± 2.26
Drug-serum 24	40min	5.91 ± 2.21
Drug-serum 24	80min	4.48 ± 1.20V

Note: #: P<0.05, ##: P<0.01, compared with Normal Saline group

*: P<0.05, compared with FMLP group

V: P<0.05, compared with DMSO group.

5 No.22 or No.24 is the samples of drug products
produced with new techniques; No.29 is a previous
drug product produced with different techniques.

EXAMPLE 3

Studies of Pharmacodynamics

10 In the studies in vitro, the drug product of *Flos*
Lonicerae, *Fructus Forsythiae* and *Radix Scutellariae*, which
was made with extraction and refined production, can
completely inhibit the replication of four kinds of virus
at 50mg of concentration of the drug. The results of the
15 anti-virus test showed that the test drug had clear anti-
virus effect in vitro and had protective effect for the
infective mice in vivo. The result of bacteriostatic test
showed that the test drug had inhibition in varying degree
for six kinds of bacteria, such as *Staphylococcus aureus*,
20 etc. in vitro and had obvious protective effect for the
mice after infection with *Staphylococcus aureus* and
Diplococcus pneumoniae.

1. Bacteriostatic effect of the drug product in vitro

Test materials

Sample: The drug product (Diantic Tablet) was provided by National Engineering Research Center for Traditional Chinese Medicine of China. Batch number: 20000801. Dosage:
5 0.7g/tablet (equal to 15 crude drugs), 2 tablet/time, three times per day.

Strain: *Staphylococcus aureus*, *Shigella shigae*, *Bacillus coli*, *Pseudomonas aeruginosa* and *Bacillus cereus*, which were purchased from Institute of Materia Medica,
10 Chinese Academy of Medical Science.

Method: Doubling dilution method

Prepare the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* in a 10% of stock solution. Dilute the test solution with the bacteria, which was
15 cultured in bouillon for 8 hours, into 0.1% of solution with a bouillon without asepsis. And then take 0.1 ml of the dilution and respectively put it into a series of test tubes, which are contained the drug product and double diluted with an aseptic bouillon. Put the test solution
20 into an incubator at 37°C for 24 hours and observe the test result. Take other test tubes to blank control (with the bacteria and without test drug) and self control (with test drug and without the bacteria). Take each strain to parallel test.

25

Result:

The results showed that the drug product could exert inhibitory effects *in vitro* for gram-positive cocci, gram-positive bacilli, and gram-negative bacilli in varying
30 degrees and illustrated that its anti-microbial spectrum is broad. The bacteriostatic effects of the drug product are shown in Table 17.

Table 17 Bacteriostatic Effects of the drug product

Group	Drug dilution rate									self control	blank control
	Orig -nal	1: 2	1:4	1:8	1:16	1:32	1:64	1:128	1:256		
Staphy- lococcus aureus	-	-	-	-	-	-	-	+	+	-	+
Shigella shigae	-	-	+	+	+	+	+	+	+	-	+
Diplococcus pneumoniae	-	-	-	-	-	+	+	+	+	-	+
Bacillus coli	-	-	-	-	-	-	+	+	+	-	+
Bacillus cereus	-	+	+	+	+	+	+	+	+	-	+
Bacillus pyocyaneus	-	-	-	-	+	+	+	+	+	-	+

"-" : no inhibition; "+" : inhibition

2. Effect of the drug product for *Staphylococcus aureus*
5 and *Diplococcus pneumoniae* in mice

Strain: *Staphylococcus aureus* and *Diplococcus pneumoniae*, which were purchased from Chinese Academy of Preventive Medical Science.

Animal: The Kunming mice were provided by Institute of
10 Materia Medica, Chinese Academy of Medical Science.

Method: 80 health mice (18-22g) with equal number of
males and females were randomly divided into four groups,
20 mice for each group. The *Staphylococcus aureus* with
Gastric Mucin (10^8 /ml) were intraperitoneally injected to
15 the mice, in a ratio of 0.2ml/10g weight for test group
and 0.5ml/20g weight for the control group. The mice were
continuously injected for five days and observed for seven
days. Their dietary activities and the number of death

were recorded. Other 80 mice were divided into groups and take the same method to test. The *Diplococcus pneumoniae* were intraperitoneally injected to the mice in a ratio of 1.2×10^8 /ml and 1.2ml/10g weight. The result showed that the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* (Diantic tablet) had protective effect for the mice with the infection of *Staphylococcus aureus* and *Diplococcus pneumoniae*. The test result was showed in the Table 18.

10 Table 18 Effects of the drug product for the mortality of bacteria

Group	Dosage	Animal	<u><i>Staphylococcus aureus</i></u>			<u><i>Diplococcus pneumoniae</i></u>		
			Death No.	Mortality	P	Death No.	Mortality	P
Blank	-	20	18	90		17	85	
Test 1	0.72	20	10	50	<0.05	9	45	<0.05
Test 2	1.44	20	8	40	<0.01	8	40	<0.01

3. Inhibitory Effect of the drug product for the Influenza Virus A1

15 Virus: Influenza A, RSV, ADV3, HSV-II were purchased from Chinese Academy of Preventive Medical Science.

Control drug: Moroxydine hydrochloride tablet, batch number: 950715-2.

20 Cytotoxicity test: The test drug and the positive control drug were respectively diluted into the solution of 1%, 5%, 10%, 15% and 20% with the cell maintenance media. Take the diluent with the concentration of 0.6%-12% and put

them into the test tubes lined with monolayer cell. Every percentage of the diluent was inoculated to four tubes. The inoculating tubes were observed at 35°C for 5-7 days. The result showed that the development of cells lined in
5 the tube was well at the range of concentration from 1% to 20% of the drug products, both tablet and granule. The result illustrated that the drug products, both tablet and granule had no toxicity for the cells at the range of concentration.

10 Dosage of inoculation: Every kind of virus was diluted into a titer of 1000TCD₅₀/0.1ml with cell maintenance media. The amount of 0.1ml of the dilution was inoculated into each tube with the monolayer Holn cells at 37°C. The diluent was absorbed for 2 hours.

15 Method

Inhibitory effect of the drug product for virus was observed with the method of Cytopathic Effect (CPE). According to the result of viral toxicity test, the titer of the virus was 1000TCD₅₀/0.1ml. The four kinds of virus
20 above-mentioned were respectively diluted into a titer of 1000TCD₅₀/0.1ml with the cell maintenance media. The influenza virus included four blood-clotting units and separately infected the cell tubes in the five groups. Each group comprised four tubes. The 0.1ml of virus
25 diluent in each tube was absorbed at 37°C for 2 hours. Add the diluent of the drug product to the cell tubes with 1%, 5%, 10%, 15% and 20% of concentration respectively. Culture the diluents at 35°C and observed them for 5-7 days, while controlled the drug toxicity with the virus control group and
30 set up the blank control group.

Result

In the test of anti-virus effect of the drug product in vitro, The four kinds of virus replication in the cells can be completely inhibited at 50mg/ml of concentration of the drug product. The result showed that the test drug had inhibitory effect for the virus in vitro. The test indicates that drug product is a kind of new dosage form of Traditional Chinese Medicine with a wide inhibitory effect for the virus proliferation, and the effect is better than Moroxydine hydrochloride tablet, as a control drug. The result is showed in the Table 19.

Table 19 Inhibitory Effect of the drug product for the virus

Test Drug	Percent- tage (%)	Concen- tration (mg/ml)	<u>Virus</u>			
			Influenza	RSV	ADV3	HSV-II
Diantic	1	10	-	+	-	-
Tablet	5	50	-	-	-	-
	10	100	-	-	-	-
	15	150	-	-	-	-
	20	200	-	-	-	-
Moroxy- dine hydro- chloride	1	10	+	+	+	+
	5	50	-	+	+	+
	10	100	-	+	+	+
	15	150	-	+	+	+
	20	200	-	+	+	+

Note: "-": Virus proliferation was inhibited and no pathologic change was found in the cells.

"+": The cell had pathologic change.

4. Effect of the drug product for the mice with
5 influenza A1

Material

Virus: The influenza virus purchased from Chinese Academy of Preventive Medical Science.

Animal: The Kunming mice provided by Institute of
10 Materia Medica, Chinese Academy of Medical Science. The number of Quality Certificate is 01-3001.

Method

The mice were randomly divided into three groups. The equal number of 100 mice was used for the virus control
15 group, the test group and the drug control group. A total of 0.03ml of influenza A1 with 10^{-2} (?) of titer was inoculated to the each of mice. The test drug was immediately given after intranasal vaccination. A total of 0.4ml/20mg of the drug product (contain 7.5g/kg of raw
20 material) was given for the drug control group with virus and drug control group (virus free). The test drug was given again after a period of 6 hours of administration. And then, the test drug was given one time everyday for 9 days. The test was observed for a period of 10 days and
25 recorded for many times everyday, including the time of death of mice each. The result showed that the mortality of infected mice with influenza A1 had significantly difference ($P < 0.01$) between the test group, the drug control group and the virus control group. It indicated
30 that the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* had greater protective effect for the

infected mice with the influenza virus. The result was showed in the Table 20.

Table 20 Inhibitory effect of the drug product for the influenza virus A1

Group	Cases	Survival No.	Death No.	Death rate(%)	P
Blank	100	5	95	85	
Test drug	100	10	81	81	<0.01

- 5 Note: Blank control: the virus control group which only contains virus.

5. Effect of the drug product for xylene-induced inflammation in the ears of mice

- 10 A total of 40 common male mice (18-20g) were divided into four groups. They were administered the sample drug products (1.44g/kg, 0.72g/kg) in the test groups, or were given the equivalent NS (0.5ml/20g). The 0.03ml of xylene was injected into the left ear of mice in order to cause
 15 inflammation for at least 3 hours. The mice were later killed and the ears were weighed. The swelling degree indicated a difference in weight between the normal ear and the inflammatory one. The results showed that the drug product of Flos Lonicerae, Fructus Forsythiae and Radix
 20 Scutellariae had a significant inhibition for xylene-induced inflammation in mice's ear. (Table 21)

Table 21 Effect of the drug product on xylene-induced inflammation in the ears of mice

25

Group	Dosage(g/kg)	No.of mice	Post-test Weight of Ear(mg, $\bar{X} \pm SD$)	P Value
Blank	---	10	5.63 \pm 2.24	
Test 1	1.44	10	4.37 \pm 1.80	<0.05
Test 2	0.75	10	4.02 \pm 1.50	<0.05

Note: Test group 1 or test group 2 was given different dosage of the sample of drug product produced with new techniques.

6. Effect of the drug product on swelling toes in rats

5 A group of 50 rats with an equal number of male and female (weight of 180-250g) were randomly divided into five groups. The volume of toes were measured and used for the normal value. The drug product of Flos Lonicerae, Fructus Forsythiae and Radix Scutellariae had a concentration of 10 1.44g/kg or 0.72g/kg in the experimental groups, and 10ml/kg of the equivalent NS was given to the control group. 0.1ml of 10% fresh albumen was injected into the toes of hind limbs to produce inflammation. The swelling degree of toes was measured for 0.5hr, 1hr, 2hrs and 4hrs 15 after the administration. The result in the test groups showed that the drug product had an evident inhibition for the albumen-induced swelling toes for four consecutive hours (Table 22). The result indicated that the drug product had a powerful inhibition on the inflammation.

20

Table 22 Effect of the drug product on swelling toes in rats

Group	Dose No	<u>Swelling (ml, $\bar{X} \pm SD$)</u>				
	(g/kg)					
		0.5h	1h	2h	3h	4h

Blank	--	10	0.63±0.18	0.66±0.17	0.57±0.16	0.52±0.16	0.37±0.03
Test 1	1.44	10	0.51±0.17	0.45±0.14**	0.40±0.12*	0.37±0.02*	0.21±0.06*
Test 2	0.72	10	0.53±0.19	0.48±0.16*	0.44±0.10*	0.41±0.09*	0.27±0.07

Note: *: P<0.05, **: P<0.01, compared with the control group.

Test group 1 or test group 2 was given different dosage of the sample of drug product produced with new techniques.

7. Effect of the drug product for artificial pyrexia in rabbit

A total of 50 rabbits with an equal number of male and female (weight of 2.0-3.0kg) were randomly divided into five groups. The normal temperature of each rabbit was measured twice within an interval of 30 minutes. The drug products were given with 1.0g/kg or 0.5g/kg of concentration and 2ml/kg of volume of water. Typhoparatyphoid A and B vaccine was injected into the auricle vein with 1ml/kg of concentration. The rectal temperature was taken four times within an interval of one hour and the data was recorded from 0-4 hours after the injection. The rectal temperature was compared between the groups. The result of the test indicated that the drug product of Flos Lonicerae, Fructus Forsythiae and Radix Scutellariae was effective for pyretolysis in rabbits and became effective within 2 hours post-administration. The remission for artificial pyrexia can last over four hours. (Table 23)

Table 23 Effect of the drug product for artificial pyrexia in rabbit

Group	Dose (g/kg)	Normal Temperature	Mean Difference of post-test (\pm SD)			
			1h	2h	3h	4h
Blank	--	38.94 \pm 0.30	0.90 \pm 0.16	0.16 \pm 0.32	0.83 \pm 0.30	0.51 \pm 0.23
Test 1	1	38.77 \pm 0.37	36	0.61 \pm 0.24**	0.47 \pm 0.11**	0.23 \pm 0.11**
Test 2	0.5	38.75 \pm 0.20	0.82 \pm 0.25	0.82 \pm 0.21**	0.57 \pm 0.24*	0.26 \pm 0.20*
			0.87 \pm 0.20			

Note: *P<0.05, ** P<0.01, compared with the control group

- 5 Test group 1 or test group 2 was given different dosage of the sample of drug product produced with new techniques.

EXAMPLE 4

10 Methodology Study on the Quality Control Standards of the drug product

This invention provides a method of High Performance Liquid Chromatography and Finger Printing Spectrum (HPLC-FPS) and a systematic quality analysis for the detection and control of the extracts and drug product of *Fructus Forsythiae*, *Flos Lonicerae* and *Radix Scutellariae*.

This invention provides a method for identifying with HPLC-FPS the composition of raw materials of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* respectively, wherein the composition comprises Chlorogenic acid, Phillyrin, and Baicalin.

This invention provides a method for determining with High Performance Liquid Chromatography (HPLC) and calculating with two-point revise method the content of Chlorogenic acid, Phillyrin, Baicalin from the raw materials of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* respectively.

This invention provides a method for identifying with HPLC-FPS the composition of water extracts of *Flos Lonicerae* and *Fructus Forsythiae* respectively, wherein the said composition further comprises *Chlorogenic acid*, *Phillyrin*.

This invention provides a method for identifying with HPLC-FPS the composition of water extract of *Radix Scutellariae*, wherein the said composition comprises *Baicalin*.

This invention provides a method for determining with HPLC and calculating with two-point revise method the content of *Chlorogenic acid* from the water extracts of *Flos Lonicerae* and *Fructus Forsythiae*.

This invention provides a method for determining with HPLC and calculating with two-point revise method the content of *Phillyrin* from the water extracts of *Flos Lonicerae* and *Fructus Forsythiae*.

This invention provides a method for determining with HPLC and calculating with two-point revise method the content of *Baicalin* from the water extract of *Radix Scutellariae*.

This invention provides a method for identifying with Gas Chromatogram (GC) the main ingredients and their content

of the supercritical extracts of *Flos Lonicerae* and *Fructus Forsythiae*, wherein the ingredients further comprise β -pinene, sabinene, α -pinene and linalool.

- 5 This invention provides a method for identifying and controlling with HPLC-FPS the composition of the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae*, wherein said composition further comprises *Chlorogenic acid*, *Phillyrin*, *Baicalin*, *Caffeic acid* and
10 *Baicalein*.

This invention provides a method for determining with HPLC and calculating with two-point revise method the content of the drug product composition of *Flos Lonicerae*, *Fructus*
15 *Forsythiae* and *Radix Scutellariae* respectively, wherein the said the content of the composition further comprises *Chlorogenic acid*, *Phillyrin* and *Baicalin*.

This invention provides a method as the above-mentioned
20 for determining the content of the drug product composition of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae*. The range of content respectively is: 1.05%-1.68% for *Chlorogenic acid*, 0.10%-0.40% for *Phillyrin*, 8.71%-14.80% for *Baicalin*.

25 This invention provides a method for controlling with a 210nm-400nm wavelength of Photodiode Array Detector (PAD) the HPLC-FPS peaks of the composition from of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae*.
30 Wherein the said composition further comprise *Chlorogenic acid*, *Phillyrin*, *Baicalin*, *Caffeic acid* and *Baicalein*.

This invention provides a method for determining with HPLC-FPS the composition of raw materials and drug

product. Wherein the said method comprises the following steps: (1) Set up the chromatographic fingerprinting of *Flos Lonicerae Fructus Forsythiae* and *Radix Scutellariae* from raw materials; (2) Determine the certified
5 characteristic /comparable peaks of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* respectively, in accordance with their relative retention of chromatographic peaks; (3) Compare and determine the peaks of undetermined ingredients with the
10 characteristic/comparable peaks.

Detailed studies of quality control of the drug product

1. Standards of Raw Medical Materials

15 *Flos Lonicerae* (dry bud of *Lonicera japonica* Thumb) is mainly produced in Henan and Shandong. The product must be in accordance to the related provisions of the item of *Flos Lonicerae* listed on Page 177 in Chinese Pharmacopoeia (2000 Edition, Part I).

20

Fructus Forsythiae is the dry fruit of *Forsythia suspensa* (Thumb) Vahl. Its main producing areas are Shanxi and Henan. The product must be in accordance to the related provisions of the item of *forsythia* listed on Page
25 135 in Chinese Pharmacopoeia (2000 Edition, Part I).

Radix Scutellariae is the dry root of *Scutellaria baicalensis* Georgi. Its main producing areas are the provinces of Hebei, Heilongjiang and Neimenggu. The
30 product must be in accordance to the related provisions of the item of *Radix Scutellariae* listed on Page 248 in Chinese Pharmacopoeia (2000 Edition, Part I).

Content Determination

1) Content Determination for Chlorogenic Acid of *Flos Lonicerae* material.

a) Apparatus and Material

i) Apparatus:

5 Chromatographic Working Station: Perkin ELMER 1022 LC Plus. Pump: Perkin ELMER series 200 LC pump. Detector: PERKIN ELMER DAD 235C. Volution mixer: Shanghai Medical University Apparatus Factory. Centrifuge and deposition machine: Shanghai operation instruments factory. Bath
10 boiler: Jangsu Changhsu Medical Instrument Factory.

ii) Sample:

Standard sample: Chlorogenic acid. Purchased from the Drug and Biology Product Test Agency.

15 Sample: *Flos Lonicerae* (provided by Shanghai Huayu pharmaceutical Co. Identified by Shanghai Chinese Medicine Quality Control Supervision and Testing Station as dried buds of *Lonicera japonica* Thumb mainly produced in Shandong and Henan.

20 Regents: methanol (HPLC), re-distilled water, anhydrous acetic acid (analysis pureness).

b) Chromatographic Condition

Chromatographic Column: Inertsil ODS-3,5 μ m, 4.6mm*250mm
25 (made in Japan). Protection Column: phenomenex C18 (ODS), 4mmL*3.0mmID. Floating Phase: the proportion of methanol to water (contains 2% acetic acid) is in a ratio of about 25 to 75. Velocity of flow: 1ml/min. Testing Wavelength: 280nm. Column Temperature: room temperature.

30

c) Standard Curve

Preparation of Standard Solution: a certain amount of Chlorogenic acid dried using diphosphorus pentaoxide for 48hrs was weighed and used as the comparing solution.

Isolate it with methanol/water (1:1) (V/V). Prepare 0.5mg/ml of concentration.

Take the standard solution and inject a sample of 2.5, 5,
5 10, 15 and 20ul under Chromatographic Condition and record the sample volume and the peak areas. Calculate the following regression equation:

$A=450580+3941609.92C$; $r=0.9992$; Linear Range: 1.25ug-10ug.

10 d) Preparation of the sample solution:

Take some *Flos Lonicerae*, rub it into the powder and pass the 40 item of bolt. Weigh exactly 134mg of powder and put it into the centrifuge tube. Add 4ml of methanol/water to a mixer and mix them for 1 minute, and then ultrasonically
15 vibrate and extract for 1 minute.

Take the upper clear solution, add 4ml of methanol/water to the residue and treat the solution for 15 min under ultrasonic wave. Centrifuge and take the upper clear
20 solution. Wash the residue with 1.5ml of methanol/water and mix the cleaning solution with the upper clear solution. Scale the volume of sample solution in a 10ml of flask and filter with 0.45um of filtration before giving sample.

25

Take the sample solution under the chromatographic condition to have HPLC analysis. Calculate the ingredient content of the sample according to the two-point revise method. The formula is given as follows:

30 $CX=C1+(C2-C1)*(AX-A1)/(A2-A1)$

C1 and C2 stand for the quantities of the standard respectively.

A1 and A2 stand for the peak areas of the standard respectively.

CX and AX stand for the quantity and peak area of the sample.

d) Content determination results:

- 5 The content of *chlorogenic acid* of *Flos Lonicerae* is about 1.05%-1.68%.

2) Content determination for *phillyrin* of *Fructus Forsythiae* material.

- 10 a) Apparatus and material

i) Apparatus:

Chromatographic Working Station: Perkin ELMER 1022 LC Plus. Pump: Perkin ELMER series 200 LC pump. Detector: PERKIN ELMER DAD 235C. Volution mixer: Shanghai Medical
15 University Apparatus Factory. Centrifuge and deposition machine: Shanghai operation instruments factory. Bath boiler: Jangsu Changhsu Medical Instrument Factory.

ii) Samples:

- 20 Standard sample: *Phillyrin*, purchased from China drug and biological product testing agency.

Sample: *Fructus Forsythiae* from Chinese traditional medicine (provided by Shanghai HuaYu Pharmaceutical Co. Identified by Shanghai Supervise Agency of quality in the
25 Chinese traditional medicine as dry fruits of *Forsythia suspensa* (Thumb) Vahl which are mainly produced in Henan and Shanxi.

b) Chromatographic Condition

- 30 Chromatographic column: Inertsil ODS-3, 5 μ m, 4.6mm*250mm (Made in Japan). Protection column: phenomenex C18 (ODS), 4mm*3.0mmID. Floating phase: the proportion of acetonitrile and water is in a ratio of about 28 to 72.

Velocity of flow: 1ml/min. Detection of wavelength: 280nm.
Temperature of column: room temperature.

c) Standard Curve

5 Preparation of standard solution:

Weigh a certain ammount of phillyrin dried with P_2O_5 for 48hr as comparison, isolate it with methanol/water (1:1v/v) and prepare a solution with 0.5mg/ml of concentration.

10

Take the standard solution under the above chromatographic condition. Inject the sample solution of 2.5ul, 5ul, 10ul, and 20ul respectively and record the peak areas and the sample volume. Calculate the regression equation:

15 $A = 51826 + 1897520.24C$, $r = 0.9998$, Linear range: 1.25ug-10ug.

d) Sample Determination

Preparation of the sample solution:

- 20 Take some material of *Fructus Forsythiae* and rub it into powder and then pass the 40 item of bolt. Weigh exactly 1.072g of the powder and put it into the centrifuge tube. Add 4ml of methanol/water to a mixer and mix them for 1 minute, and then ultrasonically vibrate and extract for
- 25 15min. Centrifuge and take the upper clear solution. Washing the residue with 1.5ml of methanol/water and mixing the cleaning solution with the upper clear solution. Scaling the volume of sample solution in a 10ml of flask. Filtering the solution with 0.45um of filtration
- 30 membrane before giving sample.

Take the above sample solution under the chromatographic condition to have HPLC analysis. Calculate the ingredient content of the sample according to the two-point revise

method. The formula is given as follows: $CX = C1 + (C2 - C1) * (AX - A1) / (A2 - A1)$

C1 and C2 stand for the quantities of the standard respectively.

5 A1 and A2 stand for the peak areas of the standard respectively.

CX and AX stand for the quantity and peak area of the sample.

10 e) The results of determination:

The content of *Phillyrin* of *Fructus Forsythiae* is about 0.10%-0.40%.

3) Content Determination of *Baicalin* of *Radix Scutellariae*
15 material

a) Apparatus and Material

i) Apparatus:

Chromatographic Work Station: Perkin ELMER 1022 LC Plus.

20 Pump: Perkin ELMER series 200 LC pump. Detector: PERKIN ELMER DAD 235C. Volution mixer: Shanghai Medical University Apparatus Factory; centrifuge and deposition machine; Shanghai operation instruments factory. Bath boiler: Jangsu Changhsu Medical Instrument Factory.

25

ii) Samples:

Standard sample: *Baicalin* purchased from China Drug and Biology Product Test Agency.

Sample: *Radix Scutellariae* (provided by Shanghai Huayu
30 Medical Co. and identified as dried roots of *Scutellaria baicalensis* Georgi plant which are mainly produced in Shandong and Hebei by Shanghai Traditional Medicine Quality Supervise & Test agency;

Reagents: Methanol (HPLC), distilled water and glacial acetic acid (analytical pureness)

b) Chromatographic Condition

- 5 Chromatographic Column: Inertsil ODS-3,5 μ m, 4.6mm*250mm (made in Japan). Protection Column: phenomenex C18 (ODS), 4mm*3.0mmID. Floating Phase: the proportion of methanol and water (contain 2% acetic acid) is in a ratio of about 65 to 35. Velocity of flow: 1ml/min. Detection Wavelength: 10 280nm. Temperature of column: room temperature.

c) Standard Curve

Preparation of Standard Solution:

- Weigh exactly a certain amount of baicalin dried with P₂O₅ 15 for 48hrs as comparing solution, and isolate it with methanol/ water (1:1 v/v). Prepare the solution to 0.1mg/ml of concentration.

- Take standard solution under the chromatographic condition 20 and inject the sample of 2.5 μ l, 5 μ l, 10 μ l, 20 μ l respectively. Record the peak areas and the sample volume, and calculate the regression equation:

A=-308002+14174938.4C; r=0.9993; Linear range: 0.25 μ g-2 μ g

25 d) Sample Determination

Preparation of the sample solution:

- Take some material of *Radix Scutellariae*, rub it into powder, and pass the 40 item of bolt. Weigh exactly 100mg of powder and put it to the centrifuge tube. Add 20ml 30 solution of methanol/water to a mixer and mix them for 15 minute, then ultrasonically vibrate and extract for 15 minute. Centrifuge and take the upper clear solution. Wash the residue with 5ml of methanol/water and combine it with the upper clear solution. Scale the volume of sample

solution in a 50ml of flask. Filter it with 0.45um of filtration membrane before giving samples.

Take the above sample solution under the Chromatographic
5 Condition to have HPLC analysis. Calculate the ingredient content of the sample according to the two-point revise method. The formula is given as follows:

$$CX=C1+(C2-C1)*(AX-A1)/(A2-A1)$$

C1 and C2 stand for the quantities of the standard
10 respectively.

A1 and A2 stand for the peak areas of the standard respectively.

CX and AX stand for the quantities and peak area of the sample.

15

e) The results of determination

The content of *Baicalin* in *Radix Scutellariae* is about 3.01%-4.47%.

20 Fingerprint Chromatography of Raw Materials

1) Fingerprint Chromatography of *Flos Lonicerae*

a) Instrument and Material

i) Instrument: Waters 510 HPLC Pump (American). Waters TM
996 PDA Photodiode Array Detector Waters pump Control
25 Module. Chromatography Working Station: Millenium 32,
Pentum III, UV wave, Swirlly mixer: XW-80A; Centrifugal
precipitator: 80-1.

ii) Regent: Acetonitrile (HPLC) purchased by Shanghai
30 Xingshi Biological Engineering Co.LTD; Methol (HPLC)
purchased by Shanghai chemical regent Co.; Glacial acetic
acid and Sparklin pure distilled water.

iii) Standard product: *Chlorogenic acid*, sold by China Test Institute of medical and biological product

iv) Samples: *Flos Lonicerae* of raw Material produced in Shandong, sold by Shanghai Huayu Pharmaceutical co. Testified to the dry bud of *Lonicera Japonica Thumb* by Shanghai Quality test station of TCM.

b) Chromatographic Condition

Chromatographic Column: Inertsil ODS-3, 5 μ m, 4.6mm*250mm (made in Japan). Protecting Column: phenomenex C18 (ODS), 4mm*3.0mmID. Floating Phase: acetonitrile: 1% acetic acid solution (V/V). Temperature: room temperature (air-condition in room is between 18~22°C); Inspector: Inspector of PDA, 210~400nm whole wavelength scan.

c) Preparation of Sample Solution

Take some material of *Flos Lonicerae*, rub it into powder and pass the 40 item of bolt. Weigh exactly 187.5mg of the powder and put it into the centrifuge tube. Add 4ml of methanol/water to a mixer and mix them for 1 min, and ultrasonically vibrate and extract it for 15min. Centrifuge and take the upper solution. Wash the residue with 1.5ml of methanol/water and combine it with the upper clear solution. Scale the volume of sample solution in a 10ml of flask, and filter it with 0.45 μ m of filtration membrane before giving sample.

d) Fingerprint Chromatogram of *Chlorogenic acid* of *Flos Lonicerae* Material (HPLC-FPS)

Take the above sample solution under the Chromatographic Condition to have HPLC analysis. The result is given in Table 19. The number of the HPLC-FPS peak is about 8 at

low limit and 11 at high limit, when the peak area of the HPLC-FPS is about 2.0×10^6 and over. The 3rd peak of the HPLC-FPS is known as the characteristic peak of *Chlorogenic acid*. The condition of characteristic peak of *Chlorogenic acid* was limited under the following: Inertsil ODS-3, 5 μ m, 4.6mm*250mm of chromatographic Column, 210-400nm of testing wavelength and 18-22°C of room temperature. The sample information refers to the Auto-Scaled Chromatogram given in Figure 2.

10

Table 19 Peak Results of *Flos Lonicerae* Raw Material

Peak No.	RT	Area	Height	Amount	Units
Peak 1	6.342	493957	30721		
Peak 2	6.673	466284	20726		
Peak 3	8.702	9085333	708461		
Peak 4	9.261	514788	21747		
Peak 5	15.580	358760	20142		
Peak 6	18.533	4871688	374813		
Peak 7	19.519	1121040	75033		
Peak 8	20.059	301004	10437		
Peak 9	22.437	357890	29941		
Peak 10	27.075	762326	22938		
Peak 11	27.566	931937	21034		

2) Fingerprint Chromatogram of Material *Fructus Forsythiae*

5

a) Apparatus and Material

i) Instrument: Waters 510 HPLC Pump (American), Waters TM 996 PDA Photodiode Array Detector Waters pump Control Module. Chromatography Working Station: Millenium 32, Pentum III, UV wave. Swirlly mixer: XW-80A. Centrifugal precipitator: 80-1.

ii) Regent: Acetonitrile (HPLC) purchased by Shanghai Xingshi Biological Engineering Co., LTD. Methol (HPLC) purchased by Shanghai chemical regent Co. Glacial acetic acid and Sparklin pure distilled water.

iii) Standard product: Phillyrin purchased from Drug and Biological Product Testing Agency of China.

20

iv) Sample: *Fructus Forsythiae* of the Chinese medicine (provided by Shanghai Huayu Pharmaceutical Co. and

testified to be the dry fruits of *Forsythia suspensa* (Thumb) Vahl produced in Henan and Shanxi.

b) Chromatographic Condition

5 Chromatographic Column: Inertsil ODS-3,5 μ m, 4.6mm*250mm (made in Japan). Protecting Column: phenomenex C18 (ODS), 4mm*3.0mmID. Floating Phase: acetonitrile: 1% acetic acid solution (V/V). Temperature: room temperature (air-condition in room is between 18~22°C). Inspector: Inspector
10 of PDA, 210~400nm whole wavelength scan.

c) Sample Solution Preparation:

Take some material of *fructus forsthaie* and rub it into powder, and pass 40 item of bolt. Weigh exactly 375mg of
15 the powder and put it into the centrifuge tube. Add 4ml of methanol/water to a mixer and mix them for 1min, then ultrasonically vibrate and extract for 15 min. Centrifuge and take the upper clear solution. Wash the residue with 1.5 ml of methanol/water and combine it with the upper
20 clear solution. Scale the volume of sample solution in a 10ml of flask, and filter it with 0.45 μ m of filtration membrane before giving sample.

d) Fingerprint Chromatogram of *Fructus Forsythiae* Raw
25 Material (HPLC-FPS)

Take the above sample solution under the Chromatographic Condition to have HPLC analysis. The result is given in Table 20. The number of the HPLC-FPS peak is about 11 at
30 low limit and 14 at high limit. The peak area of the HPLC-FPS is about 2.0×10^6 and over. The 8th peak of the HPLC-FPS is known as the characteristic peak of Phillyrin. The condition of characteristic peak of Phillyrin was limited under the following: Inertsil ODS-3,5 μ m, 4.6mm*250mm of

chromatographic Column, 210-400nm of testing wavelength and 18-22°C of room temperature. The sample information refers to the Auto-Scaled Chromatogram given in Figure 3.

Table 20 Peak Results of *Fructus Fosythiae* Raw Material

Peak No.	RT	Area	Height	Amount	Units
Peak 1	10.258	814090	48518		
Peak 3	13.135	626570	42575		
Peak 4	13.525	6745808	645897		
Peak 5	14.163	589315	42302		
Peak 6	14.573	517509	21032		
Peak 7	19.890	621807	25787		
Peak 8	20.778	586221	44436		
Peak 9	22.385	4736969	432780		
Peak 10	24.774	706135	56201		
Peak 11	26.242	692217	47573		
Peak 12	27.217	1445507	35586		
Peak 13	27.946	588955	17532		
Peak 14	30.779	655429	54190		

5

3) Fingerprint Chromatogram of *Radix Scutellariae* Raw Material

a) Apparatus and Material

i) Instrument: Waters 510 HPLC Pump (American), Waters TM
 10 996 PDA Photodiode Array Detector Waters pump Control
 Module. Chromatography Working Station: Millennium 32,
 Pentium III, UV wave. Swirlly mixer: XW-80A. Centrifugal
 precipitator: 80-1.

15 ii) Regent: Acetonitrile (HPLC), purchased by Shanghai
 Xingshi Biological Engineering Co., LTD. Methol (HPLC)
 purchased by Shanghai chemical regent Co. Glacial acetic
 acid and Sparklin pure distilled water.

20 iii) Standard product: *Baicalin* purchased from Drug and
 Biological Product Testing Agency of China.

iv) Sample: *Radix Scutellariae* of the Chinese medicine (provided bby Shanghai Huayu Pharmaceutical Co. and testified to be the dry roots of *Scutellaria baicalensis* Georgi by The Chinese Medicine Quality Testing Station of Shanghai, which are mainly produced in Shandong and Hebei.

b) Chromatographic Condition

Chromatographic Column: Inertsil ODS-3, 5 μ m, 4.6mm*250mm (made in Japan). Protecting Column: phenomenex C18 (ODS), 4mm*3.0mmID. Floating Phase: acetonitrile: 1% acetic acid solution (V/V). Temperature: room temperature (air-condition in room is between 18~22°C). Inspector: Inspector of PDA, 210~400nm whole wavelength scan.

15

c) Preparation of the Sample Solution

Take some material *Radix Scutellariae* and rub it into powder, and pass 40 item of bolt. Weigh 187mg of the powder and put it into the centrifuge tube. Add 4ml of methanol/water into a mixer and mix them for 1min, then ultrasonically vibrate for 15min. Centrifuge and take the upper clear solution, and wash the residue with 1.5ml of methanol/water. Combine the sample solution with the upper clear solution. Scale the volume of sample solution in a 10ml of flask, and filter it with 0.45 μ m of filtration membrane before giving sample.

20

25

d) Fingerprint Chromatogram of Raw Material *Radix Scutellariae* (HPLC-FPS)

Take the above sample solution the Chromatographic Condition to have HPLC analysis. The result is given in Table 21. The number of the HPLC-FPS peak is about 22 at low limit and 25 at high limit. The peak area of the HPLC-FPS is about 2.0×10^6 and over. The 12th peak of the HPLC-FPS

30

is known as the characteristic peak of *Baicalin* and the 20th peak of HPLC-FPS is known as the peak of *Baicalein*. The conditions of characteristic peak of *Baicalin* and *Baicalein* were limited under the following: Inertsil ODS-
 5 3,5 μ m, 4.6mm*250mm of chromatographic Column, 210-400nm of testing wavelength and 18-22°C of room temperature. The sample information refers to the Auto-Scaled Chromatogram given in Figure 4.

10 Table 21 Peak Results of Radix Scutellariae Raw Material

Peak No.	RT	Area	Height	Amount	Units
Peak 1	14.959	2237919	227173		
Peak 2	15.816	795422	77122		
Peak 3	16.109	1368881	150941		
Peak 4	16.599	458822	49718		
Peak 5	16.912	1857671	129863		
Peak 6	19.305	1540200	98209		
Peak 7	20.148	418214	20489		
Peak 8	21.039	1760153	142473		
Peak 9	22.232	333048	37812		
Peak 10	22.382	719683	48417		
Peak 11	23.289	878561	77954		
Peak 12	23.582	63908461	2742950		
Peak 13	24.760	324362	18757		
Peak 14	25.143	684277	47331		
Peak 15	25.756	441537	31207		
Peak 16	26.414	6035150	505894		
Peak 17	26.688	7422217	356766		
Peak 18	27.544	505176	42508		
Peak 19	27.902	15993786	932298		
Peak 20	30.030	3697771	324366		
Peak 21	36.365	2645077	228485		
Peak 22	36.712	729275	46343		
Peak 23	37.711	1377723	100271		

2. Quality Standard of Intermediate

The extract powder of *Flos Lonicerae* and *Fructus Forsythiae* was obtained with CO₂ supercritical extraction and sub-boiling aqueous extraction successively. The extract of *Radix Scutellariae* was finely obtained with water extraction.

Content Determination

1) Content Determination of *Chlorogenic Acid* of *Flos Lonicerae* and *Fructus Forsythiae* extracts.

a) Apparatus and Material

i) Apparatus:

Chromatographic Work Station: Perkin ELMER 1022 LC Plus.
Pump: Perkin ELMER series 200 LC pump. Detector: PERKIN ELMER DAD 235C. Volution mixer: Shanghai Medical University Apparatus Factory. Centrifuge and deposition machine: Shanghai operation instruments factory. Bath boiler: Jangsu Changhsu Medical Instrument Factory

ii) Sample: Extracts of *Flos Lonicerae* and *Fructus Forsythiae* (provided by National Engineering Research Center of Traditional Medicine)

b) Chromatographic Condition

Chromatographic Column: Inertsil ODS--3,5um, 4.6*250mm (made in Japan). Protecting Column: phenoemenex C18 (ODS), 4mm*3.0mmID. Floating Phase: methanol: water (contains 2% acetic acid)= 25:75

Velocity of flow: 1ml/min. Testing wavelength: 280nm. Temperature of column: room temperature.

c) Standard Curve

Preparation of standard solution:

- Weigh exactly certain ammount of *phillyrin* dried with P_2O_5 for 48hr as comparison. Isolate it with methanol/water (1:1v/v) and prepare it into a sample solution with
- 5 0.1mg/ml of concentration. Take standard solution under the above chromatographic condition. Inject the sample solution of 2.5ul, 5ul, 10ul, 20ul, respectively and record the peak areas and the sample volume. Calculate the regression equation:
- 10 $A = 450580 + 3941609.92C$, $r = 0.9992$, Linear range: 1.25ug-10ug.

d) Determination of the Sample:

Preparation of the Sample Solution:

- 15 Take the powder of *Flos Lonicerae* and *Fructus Forsythiae* extracts. Weigh exactly 170.5mg of the powder and put into the centrifuge tube. Add 4ml of methanol/water into a mixer and mix them for 1 min, then ultrasonically vibrate and extract for 15 min. Centrifuge and take the upper
- 20 clear solution. Add 4ml of methanol/water solution to the residue and treat it under ultrasonic waves for 15min. Centrifuge and take the upper clear solution. Wash the residue with 1.5ml of methanol/water and combine it with the upper clear solution. Scale the volume of the sample
- 25 solution in a 10ml of flask and filter the solution with the 0.45um of filtration membrane before giving sample.

- Take the above sample solution under the Chromatographic Condition to have HPLC analysis. Calculate the ingredient
- 30 content of the sample according to the two-point revise method. The formula is given as follows: $C_x = C_1 + (C_2 - C_1) * (A_x - A_1) / (A_2 - A_1)$
- C_1 and C_2 stand for the qualities of the standard sample respectively.

A1 and A2 stand for the peak areas of the standard sample respectively.

Cx and Ax stand for the quality and the peak area of the sample.

5

e) Examples of the Content Determination

Example 1: Take the extract of *Flos Lonicerae* and *Fructus Forsythiae* and determine the content of *Chlorogenic Acid* with the above method. The result is 2.52%.

10 Example 2: Take the extracts of *Flos Lonicerae* and *Fructus Forsythiae* and determine the content of *Chlorogenic Acid* with the above method. The result is 2.93%.

Example 3: Take the extractors of *Flos Lonicerae* and *Fructus Forsythiae* and determine the content of
15 *Chlorogenic Acid* with the above method. The result is 2.15%.

The result of the content is about: 1.00%-3.30%.

20 2) Content Determination of *Phillyrin* of *Flos Lonicerae* and *Fructus Forsythiae* extracts

a) Apparatus and Material

i) Apparatus:

25 Chromatographic Work Station: Perkin ELMER 1022 LC Plus.
Pump: Perkin ELMER series 200 LC pump. Detector: PERKIN ELMER DAD 235C. Volution mixer: Shanghai Medical University Apparatus Factory. Centrifuge and deposition machine: Shanghai operation instruments factory. Bath
30 boiler: Jangsu Changhsu Medical Instrument Factory.

ii) Sample: Extracts of *Flos Lonicerae* and *Fructus Forsythiae* (provided by National Engineering Research Center of Traditional Medicine)

b) Chromatographic Condition

Chromatographic Column: Inertsil ODS-3, 5 μ m, 4.6mm*250mm
(made in Japan). Protecting Column: phenomenex C18 (ODS),
4mm*3.0mmID. Floating Phase: acetonitrile: water = 28:72.

- 5 Velocity of flow: 1ml/min. Testing wavelength: 280nm.
Column Temperature: room temperature.

c) Standard Curve

Preparation of standard solution:

- 10 Weigh exactly a certain amount of phillyrin dried with
P₂O₅ for 48hrs to use it as the comparison solution.
Dissolve with methanol/water (1:1v/v) and prepare it into
a solution with 0.5mg/ml of concentration.

- 15 Take the standard solution under the above chromatographic
condition. Inject the sample solution of 2.5 μ l, 5 μ l, 10 μ l,
20 μ l, respectively and record the peak areas and sample
volume. Calculate the regression equation:

A=51826+1897520.24C, r= 0.9998, Linear range: 1.25 μ g-10 μ g.

20

d) Determination of the Sample

Preparation of the Sample Solution:

Take the powder of *Flos Lonicerae* and *Fructus Forsythiae*
extracts. Weigh exactly 292mg of the powder and put it
25 into the centrifuge tube. Add 4ml of methanol/water into a
mixer and mixing them for 1 min, then ultrasonically
vibrate it for 15 min. Centrifuge and take the upper clear
solution. Add 4ml of methanol/water into the residue and
treat it with ultrasonic waves for another 5min.

- 30 Centrifuge and take the upper clear solution. Wash the
residue with 1.5ml of methanol/water and combine the
washings with the upper clear solution. Scale the volume
of sample solution in a 10ml of flask and filter the

solution with 0.45um of filtration membrane before giving sample.

- Take the above sample solution under the Chromatographic
- 5 Condition to have HPLC analysis. Calculate the ingredient content of the sample according to the two-point revise method. The formula is given as follows: $C_x = C_1 + (C_2 - C_1) * (A_x - A_1) / (A_2 - A_1)$ C1 and C2 stand for the qualities of the standard sample respectively.
- 10 A1 and A2 stand for the peak areas of the standard sample. Cx and Ax stand for the quality and the peak area of the sample.

e) Content Determination;

15 Example 1

Take the extracts of *Flos Lonicerae* and *Fructus Forsythiae* and determine the content of *Phillyrin* with the above method. The result is 0.66%.

20 Example 2

Take the extracts of *Flos Lonicerae* and *Fructus Forsythiae* and determine the content of *Phillyrin* with the above method. The result is 0.59%.

25 Example 3

Take the extracts of *Flos Lonicerae* and *Fructus Forsythiae* and determine the content of *Phillyrin* with the above method. The result is 0.75%.

30 The result of the content is about: 0.2%-0.5%.

3) Content Determination of Baicalin of *Radix Scutellariae* extracts

a) Apparatus and material

i) Apparatus:

Chromatographic Work Station: Perkin ELMER 1022 LC Plus.
Pump: Perkin ELMER series 200 LC pump. Detector: PERKIN
ELMER DAD 235C. Volution mixer: Shanghai Medical
5 University Apparatus Factory. Centrifuge and deposition
machine: Shanghai operation instruments factory. Bath
boiler: Jangsu Changhsu Medical Instrument Factory

ii) Sample: extracts of *Radix Scutellariae*

10 (Provided by the Chinese Medicine Pharmaceutical and
Technical Engineering Center of China)

b) Chromatographic Condition

Chromatographic Column: Inertsil ODS-3,5um, 4.6mm*250mm
15 (made in Japan). Protecting Column: Phenomenex C18 (ODS),
4mm*3.0mmID. Floating Phase: Methanol: Water (contain 2%
acetic acid)= 65:35. Velocity of flow: 1ml/min. Testing
wavelength: 280nm. Column temperature: room temperature.

20 c) Standard Curve

Preparation of Standard Solution:

Weigh a certain amount of *Baicalin* previously dried with
 P_2O_5 for 48hrs in order to be used as the comparing
solution. Isolate it with methanol/ water (1:1v/v).
25 Prepare a solution with 0.1mg/ml of concentration.

Take standard solution under the chromatographic condition
and inject a sample of 2.5ul, 5ul, 10ul, and 20ul
respectively. Record the peak areas and the sample volume,
30 and calculate the regression equation:

$A = -308002 + 14174938.4C$; $r = 0.9993$; Linear range: 0.25ug-2ug.

d) Determination of the Sample

Preparation of the sample solution:

Take the extract of *Radix Scutellariae* and weigh exactly 10mg of extract. Put it into a 100ml of flask and add methanol/water. Ultrasonically vibrate and scale the volume in the flask. Filter the sample solution with
5 0.45um of filtration membrane before injecting sample solution.

Take the above sample solution under the Chromatographic Condition to have HPLC analysis. Calculate the ingredient
10 content of the sample according to the two-point revise method. The formula is given as follows: $C_x = C_1 + (C_2 - C_1) * (A_x - A_1) / (A_2 - A_1)$ C1 and C2: stand for the qualities of the standard sample respectively.

A1 and A2: stand for the peak areas of the standard sample
15 respectively.

Cx and Ax: stand for the quality and the peak area of the sample.

e) Content Determination:

20

Example 1

Take the extracts of *Radix Scutellariae* and determine the content of Baicalin with the above method. The result is 93.4%.

25

Example 2

Take the extracts of *Radix Scutellariae* and determine the content of Baicalin with the above method. The result is 92.2%.

30

Example 3

Take the extracts of *Radix Scutellariae* and determine the content of Baicalin with the above method. The result is 91.3%.

The result of the content is about: 90.01%-93.40%.

4) Content Determination of the CO₂ Supercritical Extracts

5

a) Material

The extracts of *Flos Lonicerae* and *Fructus Forsythiae* were extracted with the CO₂ Supercritical Fluid Extraction.

10 b) Apparatus

GC-9A Gas Chromatograph Chromatopac C-E1B data processing instrument (made in Japan).

c) Test Method

15 Gas Chromatographic Condition:

Use a SE-54 elastic quart chromatographic column with a 30-meter length and a 0.32mm inner diameter. The temperature of gasification room is about 250°C. The column temperature ranges from 50-230°C, rising 4°C/min controlled by procedure. The carried gas is Nitrogen with pre-column pressure of 0.7kg/cm. The column volume is 2 ml/min. The volume of injection is 0.4ul. The detector is FID.

d) Qualitative control

25 Example 1: Use the Gas Chromatography and contrast the sample with the standard solution. When the value of TR is about 8.551min, β -pinene can be obtained. When the value of TR is about 12.926min, linalool can be obtained. The absolute peak area is about 766933.

30

Example 2: Use the Gas Chromatography and contrast the sample with the standard solution. When the value of TR is about 8.575min, β -pinene can be obtained. When the value

of TR is about 12.919min, *linalool* can be obtained. The absolute peak area is about 1138138.

Example 3: Use the Gas Chromatography and contrast the sample with the standard solution. When the value of TR is about 8.539min, β -pinene can be obtained. When the value of TR is about 12.930min, *linalool* can be obtained. The absolute peak area is about 906224.

e) GC-Chromatograph is given in Figure 8.

Fingerprint Chromatogram of Intermediate

1) Fingerprint Chromatogram of extracts of *Flos Lonicerae* and *Fructus Fosythiae*

a) Apparatus and Material

Apparatus: as the above mentioned

Standard Sample: *Chlorogenic acid* and *phillyrin* are purchased from the Drug and Biological Product Testing Agency of China.

Sample: Extracts of *Flos Lonicerae* and *Fructus Fosythia* provided by National Engineering Research Center of Traditional Medicine.

b) Chromatographic Condition

Chromatographic Column: Inertsil ODS-3, 5 μ m, 4.6mm*250mm (made in Japan). Protecting Column: phenomenex C18 (ODS), 4mm*3.0mmID. Floating Phase: acetonitrile, 1% acetic acid solution (V/V). Temperature: room temperature (air-condition in room is between 18~22°C). Inspector: testing machine PDA, whole wavelength scan of 210~400nm.

c) Preparation of the Sample Solution

- Take the extracts of *Flos Lonicerae* and *Fructus Fosythia* and rub into powder. Then pass the 40 item of bolt. Weigh exactly 107.5mg of the powder and put it into a centrifuge tube. Add 4ml of methanol/water into a mixer and mix them
5 for 1 min. Then ultrasonically vibrate it for 15min. Centrifuge and take the upper clear solution. Add 4ml of methanol/water into the residue and vibrate the solution under ultrasonic waves for another 15min and then centrifuge it. Take the upper clear solution and wash the
10 residue with 1.5ml of methanol/water. Combine it with the upper clear solution and scale the sample solution in a 10ml of flask. Filter the solution with the 0.45um of filtration membrane before giving sample.
- 15 d) Fingerprint Chromatograph of the extracts of *Flos Lonicerae* and *Fructus Fosythia*.

- Take the sample solution under the above Chromatographic Condition to have HPLC analysis. The result is given in
20 the Table 22. The number of the HPLC-FPS peak is 18 at low limit and 23 at high limit. The peak area of the HPLC-FPS is about 2.0×10^6 and over. The 8th peak of the HPLC-FPS is known as the characteristic peak of Chlorogenic acid, the 12th peak of the HPLC-FPS is known as the characteristic
25 peak of Caffeic acid and the 21st peak of the HPLC-FPS is known as the characteristic peak of Phillyrin. The conditions of characteristic peaks of Chlorogenic acid, Caffeic acid and Phillyrin were limited under the following: Inertsil ODS-3, 5 μ m, 4.6mm*250mm of
30 chromatographic Column, 210-400nm of testing wavelength and 18-22°C of room temperature. The sample information refers to the Auto-Scaled Chromatogram given in Figure 5.

Table 22 Peak results of the Extracts of *Flos Lonicerae* and *Fructus Fosythia*

Peak No.	RT	Area	Height	Amount	Units
Peak 1	2.352	590936	105532		
Peak 2	2.821	345144	31096		
Peak 3	3.094	687602	80646		
Peak 4	3.918	320428	55429		
Peak 5	4.382	395834	58174		
Peak 6	5.637	238610	12895		
Peak 7	6.991	701082	52840		
Peak 8	9.116	8294229	664171		
Peak 9	10.787	1828968	101867		
Peak 10	10.417	202222	17165		
Peak 11	10.787	1051607	58427		
Peak 12	12.086	1023319	85427		
Peak 13	13.681	1497954	135388		
Peak 14	14.015	4682829	433278		
Peak 15	14.723	284010	26563		
Peak 16	16.497	477570	18585		
Peak 17	17.082	300708	21528		
Peak 18	18.796	398406	32457		
Peak 19	19.206	707129	58308		
Peak 20	20.092	920167	58499		
Peak 21	21.019	286029	29773		
Peak 22	22.695	527555	49406		
Peak 23	27.790	1054908	23858		

5 2) Fingerprint Chromatogram of the Radix *Scutellariae*
Extract

a) Apparatus and Material

- i) Instrument: Waters 510 HPLC Pump (American), Waters TM
10 996 PDA Photodiode Array Detector Waters pump Control
Module. Chromatography Working Station: Millenium 32,

Pentum III, UV wave. Swirllly mixer: XW-80A, Centrifugal precipitator: 80-1.

- ii) Regent: Acetonitrile (HPLC) purchased by Shanghai Kingshi Biological Engineering Co.LTD; Methol (HPLC) purchased by Shanghai chemical regent Co., Glacial acetic acid and Sparklin pure distilled water.
- iii) Standard Sample: Baicalin purchased from the Drug and Biological Product Testing Agency of China.

10 b) Preparation of the Sample Solution

Take the extractor of *Radix scutellariae* and rub it into powder, and pass the 40 item of bolt. Weigh exactly 20mg of the powder, put it into the centrifuge tube and add 4ml of methanol/water into a mixer and mix them for 1 min, then ultrasonically vibrate the solution for 15min. Centrifuge it and take the upper clear solution. Add 4ml of methanol/water into the residue and vibrate it under ultrasonic waves for another 15min. Centrifuge the solution and take the upper clear solution. Wash the residue with 1.5ml of methanol/water and combine it with the upper clear solution, and scale the sample solution in a 10ml of flask. Filter the solution with 0.45um of filtration membrane before giving sample.

25

c) Fingerprint Chromatogram of the Extracts of *Radix Scutellariae*

Take the above sample solution under the Chromatographic Condition to have HPLC analysis. The result is given in Table 23. The number of peak is 4 at low limit and 5 at high limit. The peak area of the HPLC-FPS is about 2.0×10^6 and over. The 1st peak of the HPLC-FPS is known as the characteristic peak of Baicalin, the 5th peak of the HPLC-

FPS is known as the characteristic peak of Baicalein. The conditions of characteristic peak of Baicalin and Baicalein were limited under the following: Inertsil ODS-3,5 μ m, 4.6mm*250mm of chromatographic Column, 210-400nm of testing wavelength and 18-22°C of room temperature. The sample information refers to the Auto-Scaled Chromatogram given in Figure 6.

Table 23 Peak Results of the Extracts of Radix
10 Scutellariae

Peak No.	RT	Area	Height	Amount	Units
Peak 1	22.607	18749381	1496061		
Peak 2	25.072	2486083	198168		
Peak 3	26.417	10114109	766644		
Peak 4	27.509	1765044	21991		
Peak 5	29.556	442502	35154		

3. Quality Standard of the Drug Product Preparation

15 A. Content Determination

1) Content Determination of Chlorogenic Acid of the drug product

a) Apparatus and Material

i) Apparatus:

20 Chromatographic Working Station: Perkin ELMER 1022 LC Plus. Pump: Perkin ELMER series 200 LC pump. Detector: PERKIN ELMER DAD 235C. Volution mixer: Shanghai Medical University Apparatus Factory. Centrifuge and deposition machine: Shanghai operation instruments factory. Bath
25 boiler: Jangsu Changhsu Medical Instrument Factory.

ii) Sample: New drug product with the coating film (batch number is 00912).

b) Chromatographic Condition

Chromatographic Column: Inertsil ODS-3,5 μ m,
4.6*250mm (Made in Japan). Protecting Column: Phenomenex
C18 (ODS), 4mm*3.0mmID. Floating Phase: methanol: water
5 (contain 2% acetic acid) =25:75 Velocity of flow: 1ml/min.
Testing Wavelength: 280nm, column temperature: room
temperature.

c) Standard Curve

10 Preparation of Standard Solution: Weighing exactly a
certain amount of *Chlorogenic acid* dried by diphosphorus
pentaoxide for 48hr as comparing solution. Isolating it
with methanol/water (1:1) (V/V), preparing it into 0.5mg/ml
of concentration.

15

Take the standard solution and inject the sample of 2.5,
5, 10, 15 and 20ul under the Chromatographic Condition.
Record the sample volume and the peak areas. Calculate the
following regression equation:

20 $A=450580+3941609.92C$; $r=0.9992$; Linear Range: 1.25ug-10ug.

d) Preparation of the Sample

Preparation of the Sample Solution:

Take the drug product with new technique and rub the drug
25 product into powder after removing the coating, then pass
the 40 item of bolt. Weigh exactly 0.5g of the powder and
put it to a centrifuge tube. Add 4ml of methanol/water
into a mixer and mixing them for 1 min. Then vibrate the
solution under ultrasonic waves and extract it for 15 min.
30 Centrifuge it and take the upper clear solution. Wash the
residue with 1.5ml of methanol/water, combine it with the
upper clear, and scale the sample solution in a 10ml of
flask. Filter the solution with 0.45um of filtration
membrane before giving sample.

Take the sample solution under the above-mentioned chromatographic condition to perform HPLC analysis. Calculate the ingredient content of the sample according to the two-point revise method. The formula is given as follows:

$$Cx = C1 + (C2 - C1) * (Ax - A1) / (A2 - A1)$$

C1 and C2 stand for the qualities of the standard sample respectively.

A1 and A2 stand for the peak areas of the standard sample respectively.

Cx and Ax stand for the quality and the peak area of the sample.

15 e) Examples of Content Determination

Example 1

Take the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* and determine the content of Chlorogenic acid according to the above-mentioned term. The content of Chlorogenic acid is about 1.64%.

Example 2

Take the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* and determine the content of Chlorogenic acid according to the above-mentioned term. The content of Chlorogenic acid is about 1.05%.

Example 3: Take the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* and determine the content of Chlorogenic acid according to the term above mentioned. The content of Chlorogenic acid is about 1.28%.

Result: 1.05%-1.68%.

2) Content Determination of Phillyrin of the Drug Product

a) Apparatus and Material

5 i) Apparatus:

Chromatographic Working Station: Perkin ELMER 1022 LC Plus. Pump: Perkin ELMER series 200 LC pump. Detector: PERKIN ELMER DAD 235C. Volution mixer: Shanghai Medical University Apparatus Factory. Centrifuge and deposition
10 machine: Shanghai operation instruments factory. Bath boiler: Jangsu Changhsu Medical Instrument Factory
ii) Sample: New drug product with the coating film (batch number is 00912).

15 b) Chromatographic Condition

Chromatographic Column: Inerysil ODS-3,5 μ m, 4.6*250mm (Made in Japan). Protecting Column: Phenomenex C18 (ODS), 4mm*3.0mmID. Floating Phase: acetonitrile: water = 28:72. Velocity of flow: 1ml/min. Testing Wavelength: 280nm.
20 Column temperature: room temperature.

c) Standard Curve

Preparation of stabndard solution:

Weigh exactly a certain amount of *Phillyrin* dried with P₂O₅
25 for 48hrs to be used as comparing solution. Isolate it with methanol/water (1:1v/v) and prepare with it a solution with 0.5mg/ml of concentration.

Take the standard solution under the above chromatographic
30 condition. Inject a sample solution of 2.5ul, 5ul, 10ul, and 20ul respectively and record the peak areas and the sample volume. Calculate the regression equation:

A=51826+1897520.24C, r=0.9998, Linear range: 1.25ug-10ug.

d) Determination of the Sample

Preparation of the Sample solution:

- Take the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* and rub it into powder
- 5 after removing the coat and pass it into 40 item of bolt. Weigh exactly 0.5g of the powder and put it into the centrifuge tube. Add the solution of methanol/water 4ml into a mixer and mix them for 1 min. Vibrate it under ultrasonic waves and extract the solution for 15min.
- 10 Centrifuge it and take the upper clear solution. Add methanol/water 1.5ml to the residue and vibrate under ultrasonic waves for another 15 min. Centrifuge it and take the upper clear solution. Wash the residue with methanol/water 1.5ml and combine the cleaning solution
- 15 with the upper clear solution. Scale the sample solution in a 10ml of flask. Filter it with 0.45um filtration before giving sample.

- Take the above sample solution under the above-mentioned
- 20 Chromatographic Condition to have HPLC analysis. Calculate the ingredient content of the sample according to the two-point revise method. The formula is given as follows:

$$Cx = C1 + (C2 - C1) * (Ax - A1) / (A2 - A1)$$

- C1 and C2 stand for the qualities of the standard sample
- 25 respectively.

A1 and A2 stand for the peak areas of the standard sample respectively.

Cx and Ax stand for the quality and the peak area of the sample.

30

e) Examples of Content Determination

Example 1

Take the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* to be determined

according to the above-mentioned term. The content of Phillyrin is about 0.52%.

Example 2

- 5 Take the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* to be determined according to the above-mentioned term. The content of Phillyrin is about 0.61%.

- 10 Example 3: Take the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* to be determined according to the above-mentioned term. The content of Phillyrin is about 0.70%.

Result: 0.10%-0.40%.

15

3) Content Determination of Baicalin of the Drug Product

a) Apparatus and Material

i) Apparatus:

Chromatographic Working Station: Perkin ELMER 1022 LC

- 20 Plus. Pump: Perkin ELMER series 200 LC pump. Detector: PERKIN ELMER DAD 235C. Volution mixer: Shanghai Medical University Apparatus Factory. Centrifuge and deposition machine: Shanghai operation instruments factory. Bath boiler: Jangsu Changhsu Medical Instrument Factory.

- 25 ii) Sample: New drug product with the coating film (Batch number is 00912).

b) Chromatographic Condition

Chromatographic Column: Inerysil ODS-3,5 μ m, 4.6*250mm

- 30 (mada in Japan). Protecting Column: phenomenex C18 (ODS), 4mm \times 3.0mmID. Floating Phase: methanol: water (contain 2% acetic acid)= 65:35. Velocity of flow: 1ml/min. Testing Wavelength: 280nm. Column temperature: room temperature.

c) Standard Curve

Preparation of Standard Solution:

Weigh exactly a certain amount of Baicatin previously dried with P_2O_5 for 48hrs in order to be used as the
5 comparing solution. Isolate it with methanol/ water (1:1v/v). Prepare the solution with 0.1mg/ml of concentration.

Put the standard solution under chromatographic conditions
10 and inject a sample of 2.5ul, 5ul, 10ul, and 20ul, respectively. Record the peak areas and the sample volume, and calculate the regression equation:

$A = -308002 + 14174938.4C$; $r = 0.9993$; Linear range: 0.25ug–2ug.

15 d) Determination of the Sample

Preparation of the Sample Solution:

Take the drug product of *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* and rub it into powder after removing the coating, and then pass the 40 item of
20 bolt. Weigh exactly 0.1g of the powder and put it into a 50ml of bottle. Add methanol/water into a mixer and mix them for 1 min. Then vibrate under ultrasonic waves and extract it for 15 min. Scale the sample solution in a 10ml of flask. Filter it with 0.45um filtration before giving
25 sample.

Take the sample solution under the above-mentioned Chromatographic Condition to have the HPLC analysis. Calculate the ingredient content of the sample according
30 to the two-point revise method. The formula is given as follows:

$$C_x = C_1 + (C_2 - C_1) * (A_x - A_1) / (A_2 - A_1)$$

C_1 and C_2 stand for the qualities of the standard sample respectively.

A1 and A2 stand for the peak areas of the standard sample respectively.

Cx and Ax stand for the quality and the peak area of the sample.

5

e) Examples of Content Determination

Example 1

- Take the drug product of *Flos Lonicerae, Fructus Forsythiae* and *Radix Scutellariae* to be determined according to the above-mentioned term. The content of *Baicalin* is about 9.04%.
- 10

Example 2

- Take the drug product of *Flos Lonicerae, Fructus Forsythiae* and *Radix Scutellariae* to be determined according to the above-mentioned term. The content of *Baicalin* is about 9.07%.
- 15

20 Example 3

Take the drug product of *Flos Lonicerae, Fructus Forsythiae* and *Radix Scutellariae* to be determined according to the above-mentioned term. The content of *Baicalin* is about 8.71%.

- 25 Result: 8.71%-14.80%

4) Qualitative Control of Supercritical Fluid Extraction

a) Material

- The extracts of *Flos Lonicerae* and *Fructus Forsythiae* were extracted with the CO₂ Supercritical Fluid Extraction.
- 30

b) Apparatus

GC-9A Gas Chromatograph Chromatopac C-E1B data processing instrument (made in Japan)

c) Test Method

5 Gas Chromatographic Condition:

Use a SE-54 elastic quart chromatographic column with a 30-meter length and a 0.32mm inner diameter. The temperature of gasification room is about 250°C. The column temperature ranges from 50-230°C, rising 4°C/min controlled by procedure. The carried gas is Nitrogen with pre-column pressure of 0.7kg/cm. The column volume is 2 ml/min. The volume of injection is 0.4ul. The detector is FID.

d) Qualitative control

15

Example 1: Use the Gas Chromatography and contrast the sample with the standard solution. When the value of TR is about $t_{R1}=8.476$ min, β -pinene can be got. When the value of TR is about $t_{R2}=12.925$ min, linalool can be got.

20 Example 2: Use the Gas Chromatography and contrast the sample with the standard solution. When the value of TR is about 8.513 min, β -pinene can be got. When the value of TR is about 12.945 min, linalool can be got.

Example 3: Use the Gas Chromatography and contrast the sample with the standard solution. When the value of TR is about 8.524 min, β -pinene can be got. When the value of TR is about 12.828 min, linalool can be got.

C. Fingerprint Chromatogram of the drug product

30

1) Apparatus

Waters 510 HPLC Pump (American), Waters TM 996 PDA Photodiode Array Detector Waters pump Control Module.

Chromatography Working Station: Millenium 32, Pentum III,
UV wave. Swirlly mixer: XW-80A. Centrifugal precipitator:
80-1.

5 2) Materia

- a) Regent: Acetonitrile (HPLC) purchased by Shanghai
Xingshi Biological Engineering Co., LTD. Methol(HPLC)
purchased by Shanghai chemical regent Co. Glacial acetic
acid and Sparklin pure distilled water.
- 10 b) Standard Sample: *Chlorogenic acid*, *Phillyrin* and
Baicalin that are purchased from Institute of Drug and
Biological Product Testing of China.
- c) Sample: New drug product with coating film (Batch
number is 00912).
- 15 d) Reference: refer to published references of the HPLC-
FPS of *Caffeic acid* and *Baicalein*.

2) Chromatographic Condition

- Chromatographic column: as the above mentioned: Inertsil
- 20 ODS-3,5 μm , 4.6mm*250mm (made in Japan). Protecting
Column: phenomenex C18 (ODS), 4mm*3.0mmID. Floating
Phase: acetonitrile: 1% acetic acid (V/V). Temperature:
room temperature (air-condition in room is between
18~22°C). Testing machine: Inspector PDA, whole wavelength
25 scan of 210~400nm.

3) Preparation of the Sample Solution

- Take the drug product of *Flos Lonicerae*, *Fructus*
- 30 *Forsythiae* and *Radix Scutellariae* and rub it into powder
after removing the coating, then pass of the 40-item bolt.
Weigh up exactly 200mg of the powder and put it into the
centrifuge tube. Add 4ml of methanol/water into a mixer
and mix it for 1 min. Then ultrasonically vibrate and

extract the solution for 15min. Centrifuge it and take the upper clear solution. Add 4ml of methanol/water to the residue and ultrasonically vibrate it for another 15min. Centrifuge it and take the upper solution. Wash the residue with 1.5ml of methanol/water and combine it with the upper clear solution. Scale the sample solution in a 10ml of flask. Filter the solution with 0.45um filtration before giving sample.

4) Fingerprint Chromatogram of the drug product (HPLC-FPS)

Take the above sample solution and have HPLC analysis under the above-mentioned Chromatographic Condition. The result is given in Table 24. The number of peak is about 27 at low limit and 30 at high limit, when the peak area of the HPLC-FPS is over 1.95×10^6 . In the HPLC-FPS Peak Results, the 4th of peak was known as the characteristic peak of *Chlorogenic acid*. The 5th peak was known as the characteristic peak of *Caffeic acid*. The 21st peak was known as the characteristic peak of *Phillyrin*. The 22nd and the 30th peaks were respectively known as the characteristic peaks of *Baicalin* and *Baicalein*. The conditions of characteristic peaks of *Chlorogenic acid*, *Caffeic acid*, *Phillyrin*, *Baicalin* and *Baicalein* were limited under the following: Inertsil ODS-3, 5 μ m, 4.6mm*250mm of chromatographic Column, 210-400nm of testing wavelength and 18-22°C of room temperature. The sample information refers to the Auto-Scaled Chromatogram given in Figure 7.

Table 24 HPLC-FPS of the drug product

Peak No.	RT	Area	Height	Amount	Units
Peak1	4.452	205592	38707		
Peak2	6.224	299812	21033		
Peak 3	7.120	197099	11059		

Peak 4	8.969	859033	80929
Peak 5	12.893	289803	13870
Peak 6	13.469	388059	33424
Peak 7	13.664	1081332	89657
Peak 8	14.455	249863	11072
Peak 9	14.935	229019	10680
Peak 10	15.381	371728	18089
Peak 11	15.702	361194	19883
Peak 12	16.396	530822	29253
Peak 13	16.962	322271	14947
Peak 14	17.239	822033	50090
Peak 15	17.846	469827	18948
Peak 16	18.359	305826	19057
Peak 17	19.070	267976	14063
Peak 18	19.360	572454	34344
Peak 19	19.826	213452	11461
Peak 20	20.448	830745	38803
Peak 21	21.207	384227	22545
Peak 22	22.062	47506934	3066456
Peak 23	22.941	291756	15251
Peak 24	23.383	218783	12559
Peak 25	23.804	240257	11245
Peak 26	24.784	2353400	167244
Peak 27	25.128	733507	65959
Peak 28	26.174	2952888	262798
Peak 29	26.800	229318	20662
Peak 30	29.537	722352	60740

What is claimed is:

1. A composition comprising effective amount of
5 extracts from *Flos Lonicerae Fructus Forsythiae* and
Radix Scutellariae and a suitable carrier.
2. An antiviral and antibacterial pharmaceutical
composition comprising effective amount of *Flos*
Lonicerae Fructus Forsythiae and *Radix Scutellariae*
10 and a pharmaceutically acceptable carrier.
3. A composition of claim 1 or 2, wherein the ratio of
is approximately 1:2:1.
4. A method for identifying the composition of *Flos*
Lonicerae raw material, which comprises the steps
15 of:
 - a) Using Chlorogenic acid as the standard and
using *Flos Lonicerae* raw material as a
sample;
 - b) Preparing the sample solution of *Flos*
20 *Lonicerae* raw material;
 - c) performing the Fingerprint Chromatogram (HPLC-
FPS) of *Flos Lonicerae* raw material under the
following conditions:

Conditions of Raw Material HPLC-FPS

Chromato- graphic Column	Protectin g Column	Floating Phase	Tempera- ture	Inspector	Injection Volum	Run Time (min)
Inertial ODS-3,5µm 4.6mm*250mm	phenomene x C18(ODS), 4mm*3mmID	1% acetic acid solution	room tempera- ture	PDA210~400nm of wavelength scan	5.00µl	35

25

- d) calculating the value in accordance with the
following calculating formula:

$$Cx = C1 + (C2 - C1) * (Ax - A1) / (A2 - A1)$$

C1 and C2: quantities of the standard.

A1 and A2: peak areas of the standard.

Cx and Ax: quantity and peak area of the sample.

- e) The HPLC-FPS of Flos *Lonicerae* raw material:
5 The amounts of peaks are 8 at low limit and 11 at high limit, when the peak area is over 2.0×10^6 .

5. A method for identifying the composition of *Fructus Forsythiae* raw material, which comprises the steps of:

10

- a) using Phillyrin as the standard, and use the Chinese *Fructus Forsythiae* raw material as the sample;
b) weighing exactly 375mg of the powder of *Fructus Forsythiae* raw material;
15 c) performing HPLC-FPS of *Fructus Forsythiae* raw material wherein the amounts of peaks are 11 at low limit and 14 at high limit, when the peak area is over 2.0×10^6 .

20 6. A method for identifying the composition of *Radix Scutellariae* raw material, which comprises the steps of:

- a) using Baicalin as the standard and use the Chinese *Radix Scutellariae* as the sample;
25 b) weighing appropriate amount of *Radix Scutellariae* raw material and prepare the sample solution;
d) performing the HPLC-FPS of *Radix Scutellariae* raw material and calculating the value of HPLC-FPS of *Radix Scutellariae*'s raw material wherein there are
30 22 peaks at low limit and 25 at high limit, when the peak area is over 2.0×10^6 .

7. A method for identifying the composition comprising extracts of Flos Lonicerae and Fructus Forsythiae, which comprises the steps of:
- a) using the Chlorogenic acid and Phillyrin respectively as the standard, and use the extracts of Flos Lonicerae and Fructus Forsythiae as a sample.
 - b) preparing the sample solution of the drug substance, further comprising the steps of:
 - i) taking some Flos Lonicerae and Fructus Forsythiae, rub it into powder and then pass the 40 item of bolt.
 - ii) weighing exactly appropriate amount of the powder and put it into the centrifuge tube.
 - iii) adding appropriate amount of organic solvent to dissolve the extract;
 - iv) Shaking the mixture ultrasonically and take the upper solution;
 - v) repeating the above extraction procedure if necessary;
 - vi) Washing the residue with the organic solvent and combine the extract;
 - vii) filtering the extract if necessary;
 - c) performing the HPLC-FPS of the drug substance of Flos Lonicerae and Fructus Forsythiae, under the following conditions:

25 Conditions of HPLC-FPS of Drug Substance

Chromato- graphic Column	Protectin g Column	Floating Phase	Tempera -ture	Inspector	Injectio n Volum	Run Time (min)
Inertsil ODS-3,5µm 4.6mm*250mm	phenomene x C18(ODS), 4mm*3mmID	1% acetic acid solution	room tempera -ture	PDA210~400nm whole wavelength scan	20.00µl	35

d) determining the peaks created by the analysis wherein the amounts of peaks are 18 at low limit and 23 at high limit, when the peak area is over 2.0×10^6 .

- 5 8. A method for identifying with HPLC-FPS the composition of the drug substance of Radix Scutellariae, which further comprises the steps of:
- a) using Baicalin as the standard solution and use the extract of Radix Scutellariae as the sample solution;
- 10 b) weighing exactly 20 mg of the powder of Radix Scutellariae and preparing the sample solution of the extract;
- c) Performing the HPLC-FPS of the Radix Scutellariae extract;
- 15 d) determining the profile of HPLC-FPS of Radix Scutellariae extract, wherein the amounts of peaks are 4 at low limit and 5 at high limit, when the peak area is over 2.0×10^6 .

- 20 9. A method for preparing a pharmaceutical composition of Fructus Forsythiae and Flos Lonicerae, wherein the drug substance of Fructus Forsythiae and Flos Lonicerae was prepared with CO₂ supercritical fluid extraction under the control of homogeneous design.

25

10. A method of claim 9, further comprising the steps of:
- (a) preparing the composition with CO₂ supercritical fluid extraction with or without aqueous alcohol under the following conditions: 8.0-14.0MP of pressure, at 32-40°C of
- 30 temperature for 1-3 hours; (b) breaking the materials into 20-60 mesh of reduction ratio and (c) obtaining a 0.1-1% of extract rate.

11. A method of claim 9, wherein the composition of Fructus Forsythiae and Flos Lonicerae was prepared with CO₂ supercritical fluid extraction containing the amount of aqueous alcohol entrainment, which is equal to 10%-90% CO₂.
- 5
12. A method for embedding with CO₂ supercritical fluid extraction the supercritical extract of Fructus Forsythiae and Flos Lonicerae, wherein the supercritical extract was embedded with saturated solution of β -cyclodextrin and the embedding rate is about 60%.
- 10
13. A method for preparing the composition of Fructus Forsythiae and Flos Lonicerae comprising the steps of: (a) Embedding the supercritical extract of Fructus Forsythiae and Flos Lonicerae with saturated solution of β -cyclodextrin; (b) Determinating the benzene content; (c) Granulating with solid dispersion technique.
- 15
14. A method of claim 9, wherein the active ingredients of the supercritical extracts comprising β -pinene, sabinene, α -pinene and linalool.
- 20
15. A method for preparing the a pharmaceutical composition comprising *Fructus Forsythiae* and *Flos Lonicerae* with subboiling aqueous extraction under the following conditions: about 80-95°C of temperature and 1-3 hours of time.
- 25
16. A method for purifying the sample solution with flocculating process, wherein the process was performed under the following conditions: the amount of flocculant is about 0.5g-3.5g/100g of raw material and when the flocculant is added the specific gravity of the sample solution is 1.01-1.35, wherein the temperature of the
- 30

sample solution with the flocculant is 35-80°C and the concentration of aqueous alcohol is about 70-95% and the specific gravity of the sample solution is 1.1-1.3, when the aqueous alcohol is added.

5

17. A method for determining with chromatography the content of Chlorogenic Acid in the Flos Lonicerae raw material comprising the steps of:

- a) using *Chlorogenic acid* as the standard solution and use Flos raw material as the sample solution.
- b) preparing the sample solution;
- c) performing the HPLC of Chlorogenic Acid content of *Flos Lonicerae* raw material under the condition:

Conditions of HPLC-FPS of Raw Material Content

Chromato- graphic Column	Protectin g Column	Floating Phase	Tempera- ture	Velocity of flow	Testing Wavelength h	Run Time (min)
Inertsil ODS-3,5µm 4.6mm*250m m	phenomene x C18 (ODS) 4mm*3mmID	methanol: water=25:75 (contains 2% acetic acid)	room tempera- ture	1ml/min	280nm	35

15

- d) determining the content of Chlorogenic Acid of Flos Lonicerae raw material:

Example: i) 1.85%; ii) 2.34%; iii) 1.51%. The result of the content is about 1.05%-1.68%.

20

18. A method for determining with chromatography the content of Phillyrin of Fructus Forsythiae raw material comprising the steps of:

- a) Using Phillyrin as the standard solution and use Fructus Forsythiae raw material as the sample solution.
- b) taking appropriate amount of the powder of Fructus Forsythiae and preparing the sample solution;

- c) performing the HPLC of Fructus Forsythiae raw material under the appropriate conditions;
- d) determining the content of Phillyrin of Fructus Forsythiae raw material wherein the content is about
5 0.10%-0.40%.

19. A method for determining with chromatography the content of Baicalin of Radix Scutellariae raw material comprising the steps of:

- 10 a) using Baicalin as a standard and Radix Scutellariae raw material as a sample.
- b) preparing sample solution comprising the radix scutellariae;
- c) perform the HPLC of Radix Scutellariae raw material
15 under the appropriate conditions; and
- d) determining the content of Baicalin of Radix Scutellariae raw material, wherein the content is about 3.01%-4.47%.

20 20. A method for determining with chromatography the Chlorogenic Acid content of composition of Fructus Forsythiae and Flos Lonicerae comprising the steps of:

- 25 a) using the composition of Fructus Forsythiae and Flos Lonicerae as a sample.
- b) preparing the sample solution having the composition of Flos Lonicerae and Fructus Forsythiae
- c) Calculate Chlorogenic Acid content of the sample according to the formula of claim 1.
- 30 d) Determining Chlorogenic Acid content, wherein the chlorogenic acid content is about 1.00%-3.30%.

21. A method for determining with chromatography the content of Phillyrin of the composition of Fructus Forsythiae and Flos Lonicerae comprising the steps of:
- a) preparing the sample solution comprising Fructus Forsythiae and Flos Lonicerae;
 - b) calculating the Phillyrin content of the sample and
 - c) determining Phillyrin content of the drug substance, wherein the Phillyrin content is about 0.2%-0.5%.
22. A method to determine by chromatography the content of Baicalin in the drug substance of Radix Scutellariae comprising the steps of:
- a) preparing the sample solution comprising Radix Scutellariae;
 - b) calculating Baicalin content of the sample; and
 - c) determining Baicalin content of the drug substance wherein the Baicalin content is about 90.01%-93.40%.
23. A method for determining with chromatography the content of supercritical extract from Fructus Forsythiae and Flos Lonicerae, comprising the steps of:
- a) Determine the relative content under the following conditions:
 - i) Gas Chromatographic: SE-54 elastic quartz capacity. Chromatographic column with a 30-meter length and a 0.32mm inner diameter. Gasification room temperature of 250°C. Column temperature ranges from 50-230°C rising 4°C/min controlled by procedure.
 - ii) Gas carried to be Nitrogen with pre-column pressure of 0.7kg/cm.
 - iii) Column flow rate of 2ml/min, giving sample quality of 0.4ul.
 - b) Content of supercritical extract of Fructus Forsythiae and Flos Lonicerae:

- i) Contrast with the standard sample when
tR=8.551min, β -pinene can be obtained. When
tR=12.926min, linalool can be obtained. The absolute
peak area is about 766933.
- 5 ii) Contrast with the standard sample when
tR=8.575min, β -pinene can be obtained. When
tR=12.919min, linalool can be obtained. The absolute
peak area is about 1138138.
- 10 iii) Contrast with the standard sample when
tR=8.539min, β -pinene can be obtained. When
tR=12.930min, linalool can be obtained. The absolute
peak area is about 906224.
- c) GC-Chromatograph is given in Figure 8.
- 15 24. A method for determining with GC-MS the supercritical
extract of *Fructus Forsythiae* and *Flos Lonicerae*, wherein
the values of GS-MS of the supercritical extract were
shown in the following examples:
- β -pinene should be obtained at 8.551 min of RT (Retention
20 Time). Linalool should be obtained at 12.926 min of RT.
The absolute peak area is about 766933;
- β -pinene should be obtained at 8.575 min of RT. Linalool
should be obtained at 12.919min of RT. The absolute peak
area is about 1138138;
- 25 β -pinene should be obtained at 8.539 min of RT. Linalool
should be obtained at 12.930 min of RT. The absolute peak
area is about 906224.
- 30 25. A composition deriving from raw herbal materials
comprising about 1 part of *Flos Lonicerae*, 2 parts of
Fructus Forsythiae and 1 part of *Radix Scutellariae*.

26. A formula of a product comprising about 90-180 parts of soft extract of *Flos Lonicerae* and *Fructus Forsythiae*, about 10-60 parts of supercritical extract of *Flos Lonicerae* and *Fructus Forsythiae*, about 30-50 parts of
5 *Radix Scutellariae* extract and about 23-125 parts of excipients.

27. A composition of 25 or 26 for preparing a product product, wherein said constituents are presented in the
10 following range: about 0.01 percent to about 99.99 percent of effective constituents, and about 99.99 percent to 0.01 percent of medical excipients.

28. A composition as in claim 25, wherein said
15 constituents are presented in the following formula: about 10 percent to 100 percent of *Flos Lonicerae*, 10 percent to 100 percent of *Fructus Forsythiae*, and 10 percent to 100 percent of *Radix Scutellariae*.

20 29. A composition as in claim 25, wherein said constituents are further composed of about 1.3 percent to 1.6 percent of Chlorogenic acid, 0.2 percent to 0.3 percent of Phillyrin and about 14.1 percent to 15.3 percent of Baicalin.

25

30. An antiviral composition for inhibition of comprising herbals of *Radix Scutellariae*, *Fructus Forsythiae* and *Flos Lonicerae*.

30 31. The composition of claim 30, wherein virus is herpes I virus, herpes II virus, influenza virus, parainfluenza virus or Human immunodeficiency virus.

32. An antibacterial composition for inhibition of comprising herbals of Radix Scutellariae, Fructus Forsythiae and Flos Lonicerae.


5

10

15


1/7

Figure 1. Flow chart for Chitosan preparation




2/7

FIGURE 2. 3D-Spectro-Chromatogram of Flos Lonicerae


Sample Information

SampleName	jln yaocai	Sample Type	Unknown
Vial	1	Date Acquired	12/19/2000 3:49:19 PM
Injection	1	Acq Method Set	zou
Injection Volume	5.00 ul	Processing Method	a
Channel	996	Date Processed	7/6/2001 5:22:56 PM
Run Time	35.0 Minutes		

Auto-Scaled Chromatogram

3/7

FIGURE 3. 3D-Spectro-Chromatogram of Fructus Forsythiae




Sample Information

SampleName lian yaocal
Vial 1
Injection 1
Injection Volume 5.00 ul
Channel 996
Run Time 35.0 Minutes


Sample Type Unknown
Date Acquired 12/19/2000 4:39:07 PM
Acq Method Set zou
Processing Method a
Date Processed 7/6/2001 5:27:43 PM

Auto-Scaled Chromatogram



4/7

FIGURE 4. 3D-Spectro-Chromatogram of Radix Scutellariae




Sample Information

SampleName huanqinyaocai
Vial 1
Injection 2
Injection Volume 20.00 ul
Channel 996
Run Time 40.0 Minutes


Sample Type Unknown
Date Acquired 4/6/2000 4:25:38 PM
Acq Method Set zou
Processing Method a
Date Processed 7/6/2001 5:41:20 PM

Auto-Scaled Chromatogram



5/7


FIGURE 5. 3D-Spectro-Chromatogram of extract of Flos Lonicerae and Fructus Forsythiae



Sample Information


SampleName	jln+lian tiqwu	Sample Type	Unknown
Vial	1	Date Acquired	12/19/2000 11:48:37 AM
Injection	1	Acq Method Set	zou
Injection Volume	20.00 ul	Processing Method	a
Channel	996	Date Processed	7/6/2001 4:58:57 PM
Run Time	35.0 Minutes		

Auto-Scaled Chromatogram



6/7

FIGURE 6. 3D-Spectro-Chromatogram of the extract of Radix Scutellariae




Sample Information

SampleName huanqincupin
Vial 1
Injection 1
Injection Volume 20.00 ul
Channel 996
Run Time 35.0 Minutes


Sample Type Unknown
Date Acquired 12/19/2000 12:52:39 PM
Acq Method Set zou
Processing Method a
Date Processed 7/6/2001 4:50:07 PM

Auto-Scaled Chromatogram



7/7


FIGURE 7. 3D-Spectro-Chromatogram of drug product of Flos
Lonicerae, Fructus Forsythiae and Radix Scutellariae



Sample Information

SampleName suanhuanlian
Vial 1
Injection 1
Injection Volume 20.00 ul
Channel 996
Run Time 35.0 Minutes

Sample Type Unknown
Date Acquired 12/19/2000 1:55:34 PM
Acq Method Set zou
Processing Method a
Date Processed 12/19/2000 3:40:06 PM



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.